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1.0 Abstract  
DNA double-strand breaks (DSBs) are known to be the most deleterious of lesions and if left 
unrepaired, may result in apoptosis or gross chromosomal rearrangements. The non-
homologous end joining (NHEJ) pathway is the main repair pathway for DSBs, and defects 
in the pathway have been shown to cause genomic instability and contribute to 
tumourigenesis. It has been shown that post-translational modifications play a large role in 
the control and regulation of the NHEJ pathway, and therefore present attractive targets to 
develop new therapies. Several components of the NHEJ pathway, including XLF, XRCC4 
and DNA Ligase IV have been suggested to undergo acetylation in response to DNA damage, 
and it is thought that this may play a role in the regulation of the NHEJ pathway. Following 
investigation, it was found that these components may become acetylated in vitro, however in 
vivo, the results were more elusive. The results suggest that XLF and XRCC4 are basally 
acetylated prior to DNA damage, but may become hyper-acetylated in response to a DSB. If 
acetylation is confirmed to play a regulatory role in the process of NHEJ, it may provide a 
target which may be exploited in order to develop novel cancer treatments and therapies. 
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2.0 Introduction 
2.1 DNA Damage and the Repair Process 
DNA damage and double strand breaks are known to be a frequent occurrence within 
eukaryotic cells. Double strand breaks (DSBs) are considered to be the most deleterious of 
lesions, and it has been estimated that 10 DSBs occur in each cell, every day (1). DSBs can 
occur through exposure to environmental factors such as ionizing radiation and genotoxic 
chemicals. They may also occur as a result of certain endogenous processes including normal 
cell metabolism, DNA replication and gene rearrangements in lymphocytes, known as ‘VDJ 
recombination’ (2). In order to maintain genomic integrity and cell viability, cells possess 
two main mechanisms of repairing damaged DNA; homologous recombination (HR) and the 
non-homologous end joining (NHEJ) pathway (1,3). These two pathways complement each 
other, and are sometimes interchangeable; however they function optimally under different 
circumstances (2). Failure to repair DNA can lead to permanent cell cycle arrest, apoptosis or 
mitotic cell death as a result of the loss of genomic material (1). In addition, defects in the 
DNA repair process can lead to gross chromosomal rearrangements, loss of genomic 
integrity, and can ultimately contribute to tumourigenesis (1,2).  
Homologous recombination (HR) maintains genomic integrity by promoting the accurate 
repair of DSBs through the use of a template strand of DNA (3). For this reason, HR is the 
primary method of repair during the late S and G2 phases of the cell cycle; when sister 
chromatids are readily available (4).  
 
The NHEJ pathway is the primary route of repair during Go and G1 phases of the cell cycle 
(3,4). It is referred to as ‘non-homologous’ as it carries out repair without the use of a 
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template strand of DNA; for this reason this pathway is error-prone, and sequence 
information can often be lost when the strands are re-joined (5).  
 
2.2 The Non-Homologous End Joining Pathway 
The NHEJ pathway is not only essential for the repair of DSBs, but also for the re-ligation of 
DNA ends generated during the process of VDJ recombination. As a result of this, 
individuals who have defects in the NHEJ pathway also suffer immunodeficiency, as well as 
hypersensitivity to ionizing radiation (4,5). NHEJ provides an efficient mechanism of DSB 
repair throughout all stages of the cell cycle, but functions optimally during the Go, G1 and 
early S phases (5). Following a DSB, both DNA termini are bound by a heterodimeric 
complex known as Ku70/80 (5). Ku70/80 then translocates inward along the DNA, and 
recruits and activates DNA-dependent protein kinase, catalytic subunits (DNA PKcs) to both 
of the DNA ends (2,5). This causes the subsequent activation of the serine/threonine protein 
kinase function of the complex, thereby promoting the alignment of the two DNA ends. The 
DNA PKcs interact with each other across the DSB in order to create a molecular bridge 
across the gap, and join the two DNA ends together (7). This then stimulates the 
autophosphorylation of the DNA PKcs, resulting in an alteration in the conformation and the 
dynamics of the DNA PKcs (7). This triggers the recruitment of the Artemis protein along 
with additional end-processing factors, such as Polymerase X (pol X), which work to produce 
compatible DNA ends for successful ligation (7). To complete the process, the XRCC4-DNA 
Ligase IV complex and XLF work together in order to ligate the two ends together and repair 
the lesion (Figure 1).  
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Figure 1. A Diagram to show the Process of  NHEJ in Mammals (Modified from AJ Hartlerode 
et al (2009). The process of NHEJ in mammals occurs following the incidence of a DSB. The Ku 
70/80 heterodimer binds to the DNA termini, and translocates inwards, allowing the recruitment of 
DNA PKcs. Following this, the DNA PKcs are phosphorylated and autophosphorylated, which 
triggers the recruitment of Artemis, and other polymerases. Finally the XRCC4-DNA Ligase IV 
complex and XLF co-operate to complete the ligation, and repair the break.  
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2.3 XRCC4-DNA Ligase IV Complex and NHEJ 
DNA Ligase IV and XRCC4 are essential for the successful repair of DSBs through the 
NHEJ pathway. Following DNA damage, XRCC4 and DNA Ligase IV form a tight complex 
within the cell, and interact with other proteins involved in the NHEJ pathway in order to 
ligate the two DNA ends (10). An unusual aspect to the XRCC4-DNA Ligase IV complex is 
that it is essential to the successful function of NHEJ, however it does not play a role in other 
DNA repair pathways (10). The fact that the XRCC4- DNA Ligase IV complex is specific to 
NHEJ suggests that regardless of its intrinsic ability to bind DNA, the XRCC4- DNA Ligase 
IV complex is not capable of recognizing DSBs; it must be recruited to the sites of damage 
by additional NHEJ components (10).  
XRCC4 is a 36KDa protein known to form homodimers which are capable of interacting with 
DNA (9,12). Structural studies have shown XRCC4 to be made up of three main domains; a 
globular N-terminal domain, possibly involved in DNA contacts, a coiled coil arm domain 
which mediates dimerization and DNA Ligase IV interactions, and finally, a domain 
extending to the C terminus (figure 2) (9). XRCC4 is said to activate the DNA Ligase IV 
complex, but importantly, is also essential to ensure DNA ligase IV stability (9). It has been 
previously noted that XRCC4 is phosphorylated by DNA PKcs in vivo following ionizing 
radiation (10). It can therefore be suggested that NHEJ could potentially be regulated through 
various post-translational modifications such as phosphorylation, or acetylation of various 
components of the pathway including XRCC4.  
Human DNA Ligase IV is a 91 kDa protein which is responsible for catalysing the ligation of 
lesions in the phosphodiester backbone of DNA (10). It is a member of the ATP-dependent 
DNA ligases, however its roles are specific to NHEJ and V(D)J recombination (9,10). In the 
absence of DNA Ligase IV, NHEJ does not occur, which suggests that DNA Ligase IV is an 
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essential component of NHEJ, and that it cannot be substituted for by other members of the 
ligase family (13). DNA Ligase IV functions to fully ligate DNA ends, even if they are 
incompatible; this function is stabilised and stimulated by its interactions with XRCC4 and 
XLF (10). XRCC4 is required for the stability of DNA Ligase IV, and forms a tight 
association with DNA Ligase IV in vivo (9,10).In addition, XRCC4 is not only necessary for 
the stability of DNA Ligase IV, but has also been shown to stimulate adenylation and the 
overall activity ofDNA Ligase IV in vivo and in vitro (9). Inactivation of DNA Ligase IV or 
XRCC4 causes immunodeficiency and radiosensitivity as a 
consequence of the resulting defective NHEJ (11,12). Due to 
the fact that XRCC4 is phosphorylated during NHEJ, it would 
be interesting to determine whether DNA Ligase IV undergoes 
any post-translational modifications which have regulatory 
roles within the NHEJ pathway. If so, these modifications may 
be targeted in order to potentially develop novel therapies and 
treatments to treat illnesses such as cancer.  
Figure 2: The Atomic Structure of the truncated XRCC4 Dimer, modified from Recuero-Checa 
et al. (2009). XRCC4 is made up of a globular N terminus, shown in pink, a protruding coiled-coil 
domain shown in orange, which follows through to the C-terminus (not shown).  
 
2.4 XRCC4-Like Factor (XLF) and NHEJ 
 
XRCC4-Like Factor (XLF) has recently been discovered to interact with XRCC4, the LX 
complex and has been found to be co-recruited to DSBs along with other NHEJ components 
(11). XLF has been shown to be an essential factor in the NHEJ pathway, as patients with 
loss of function mutations in XLF show radiosensitvity and immunodeficiency (10,11). 
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XLF was shown to 
share structural 
similarity to XRCC4; it 
contains a globular N-
terminal domain, and a 
C-terminal coiled-coil 
domain (figure 2) (12). 
Figure 3.Crystal structure of XLF/Cernunnos.Ribbon diagram of the XLF/Cernunnos 
dimer.Adapted from Ochi T et al. (2010). One protomer is rainbow colour going from N-terminus 
(blue) to C-terminus (red).  
 
2.5 Histone Acetyl Transferases and Histone Deacetylases 
Histones are the basic packaging unit of DNA, and they readily undergo post-translational 
modifications in order to regulate the transcription and expression of certain genes (18). 
These modifications form a certain pattern, known as the ‘histone code’ which plays a major 
role in the processes of DNA replication and also in the vital repair pathways which become 
activated after DNA damage (18, 19).  There is increasing evidence to suggest that certain 
PTMs may contribute significantly to both normal and aberrant cell behaviour and function 
(18). The PTMs are initiated by histone modifying enzymes known as histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) (20). HATs act to acetylate 
certain lysine residues on both histone and non-histone targets through the transfer of an 
acetyl group from acetyl coenzyme A (19). Acetylation of non-histone targets results in 
alterations in enzyme activity and protein-protein interactions causing variations in signal 
transduction (20). Acetylation of histone targets on the other hand, leads to changes in 
histone-DNA and histone-protein interactions consequentially affecting the accessibility of 
DNA and the ability of transcription factors to bind the DNA (19).  Acetylation is known to 
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be a dynamic process which plays a major role in the regulation of various processes 
including DNA replication, and in the DNA damage response pathway (18). The control 
comes from both the 
processes of acetylation 
and deacetylation, and 
achieving the correct 
balance between the two 
modifications (19).   
 
Figure 4. The interaction between HATs and their acetylation targets, from Dekker FJ et al. 
(2009).  Families of HATs are known to acetylate both histone and non-histone targets, resulting in 
alterations in enzyme activity, protein-protein interactions and the interactions between histones, 
DNA and proteins. Acetylation in this manner can control and regulate signal transduction, and affect 
the accessibility of DNA through the acetylation of various targets (16).  
 
HATs are organised into different families based on their structural homology (19). Two of 
the most extensively studied families are the GNAT family, which includes PCAF and 
GCN5, and the P300/CBP family which includes P300 and CBP (18, 19). PCAF and GCN5 
share 73% homology, while P300 and CBP share 60% homology (18). However PCAF and 
P300 for example only share minimal sequence and structural homology, suggesting they 
have different functions and targets (19). Due to the fact that different HATs may have a 
variety of different targets and functions, the acetylation of XLF, XRCC4 and DNA Ligase 
IV will be examined in the presence of PCAF, GCN5, P300 and CBP in order to assess which 
HAT, if any, results in the highest level of acetylation.  
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2.7 The role of Post Translational Modifications and Acetylation in NHEJ 
Post translational modifications (PTMs) are an essential and fundamental means by which 
protein function and control can be regulated. For any given protein, the chemical properties, 
activity, localisation as well as its stability may be altered through the action of various 
PTMs. (19). Of all the PTMs, phosphorylation is the most widely studied and understood. 
However, methylation, ubiquitination and acetylation, among other PTMs are also known to 
play a major role in a cellular signalling network which works to regulate various aspects of 
protein function and activity (19, 20). 
Acetylation was originally identified to be important for the modification of histones during 
transcription (19). For example, it has been shown that following exposure to damaging 
irradiation, it was observed that several upregulated genes coding for protection to UV, 
showed increased levels of histone H3 and histone H4 acetylation (21). It is now known that 
histone acetylation and chromatin modification through acetylation are essential functions 
during DNA repair; however not a vast amount is known regarding the effects of acetylation 
events on the function and regulation of DNA repair (21).  Histones are acetylated and 
deacetylated at lysine residue sites in the N-terminal tail region of proteins (22). These 
modifications are catalysed by Histone Acetyl-transferases (HATs) and Histone deacetyl-
transferases (HDACs). Acetylation has also been found to occur in non-histone proteins, and 
is now known to take place in over 80 transcriptional factors, nuclear regulators and 
cytoplasmic proteins. In this way, acetylation can be considered to be an essential factor in 
both the regulation within the nucleus as well as within the cytoplasm (22).  
 
Acetylation at lysine residues occurs within an array of different proteins, and has been 
discovered to cross-talk with other PTMs in order to create a complex modification system 
which may enable dynamic regulation of cellular signalling (23). For example, the acetylation 
10 
 
of histones H3 and H4 have been found to crosstalk with the phosphorylation of serines 10 
and 28 during signalling events within the cell (23). Due to the fact that phosphorylation is 
known to occur during DNA damage and NHEJ, and that histone acetylation also plays an 
essential role during these pathways, it can be questioned as to whether additional acetylation 
events, possibly linked with phosphorylation may occur during NHEJ.  
 
A previous study performed by Dr. Boris Kysela exposed evidence that several non-histone 
components of the NHEJ pathway undergo acetylation in response to DNA damage, in 
particular the XRCC4-DNA Ligase IV complex (Figure 5).  
 
Figure 5: A figure to show the levels of acetylation following DNA damage in several NHEJ proteins by 
three different histone acetyl transferases (HATs) (Courtesy of Dr. Boris Kysela). XLF, XRCC4, DNA 
Ligase IV (LX) and histone H1.X have undergone acetylation by histone acetyl transferases, PCAF, P300 and 
CBP with radioactive C14 acetyl coenzyme A as outlined in section 3.3.3. Unfortunately, no size markers were 
available for this piece of data, however the evidence provided by the exposure suggests that the bands correlate 
to the proteins, as labelled. Normally, H1.X, the positive control for acetylation would be seen around the 
35kDa mark, XLF would be seen at 37kDa, XRCC4 would be seen at 55kDa, and finally DNA Ligase IV would 
be expected at 96kDa. With these approximations, there are probable bands present for all NHEJ proteins with 
all HATs, suggesting that they are acetylated. Particularly strong bands can be seen for the DNA Ligase IV 
complex with PCAF, as well as H1.X with all three HATs.  
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Therefore, the aim of this project is to determine whether acetylation occurs within the 
XRCC4-DNA Ligse IV complex, XLF, and H1.X in response to DNA damage, and if so, to 
map the sites of acetylation in order to identify singular sites of acetylation, as well as 
clustered sites. If acetylation is found to play an essential role in the NHEJ pathway, new 
potential targets may be identified and could potentially be exploited in order to create new 
treatments and therapies to treat cancer. In this way, further information can be gathered 
regarding the role of acetylation in the NHEJ pathway. 
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3.0 Methods 
3.1 Cells and Cell Culture 
3.1.1 MRC5VA Cells 
MRC5VA cells were used throughout this research project, and were provided by Dr. Sarah 
Blair-Reed. MRC5VA cells are embryonic human lung fibroblast cells which have been 
immortalised by SV40 transformation. 
3.1.2 Cell Maintenance 
In order to maintain sterility, all procedures involving the cells were carried out under sterile 
conditions in a class 2 tissue culture hood (HoltenLaminAir). In addition, all solutions and 
equipment used while handling the cells were obtained sterile, or had been autoclaved prior 
to use. Cells were split and maintained routinely every 3 days by Dr. Sarah Blair-Reed.  
3.1.3 Trypsinisation of Confluent Cells 
Upon reaching confluence, the media was withdrawn from the flask with a sterile 10ml 
pipette. 10ml of phosphate buffered saline (PBS; 2.7mM KCl, 137mM NaCl, 10mM 
phosphate buffer, pH 7.4) was added to the flask in order to rinse the cells. PBS was then 
removed carefully with a 10ml pipette, after which approximately 3ml of trypsin- 
ethylenediaminetetraacetic acid (EDTA; 0.25%:0.02%, 37°C) solution was added to the flask. 
The flask was then placed in a humidified incubator at 37°C for approximately 3mins or until 
the cells have become dislodged from the bottom of the flask. The flask was then knocked 
strongly against the palm of the hand in order to further dislodge the cells. When the majority 
of cells were dislodged, 7ml of DMEM was added to the flask, and was gently pipetted up 
and down, with a sterile pipette, and finally removed from the flask and added to a fresh 15ml 
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centrifugation tube. The tube was then centrifuged for 3 mins at 15,000RPM in order to pellet 
the cells.  
 
3.1.4 Transfecting Cells with FLAG-Ligase IV 
The MRC5VA cells were seeded into 4 flasks, each with approximately 2x106cells. The cells 
were left to grow in a humidified incubator at 37ºC overnight. The following day, 90µl of 
serum free Dulbecco’s Modified Eagle’s Medium (DMEM; containing 1000mg/L glucose) 
(Sigma-Aldrich) was mixed with  3µl FuGENE  HD transfection reagent (Roche), and left in 
the fume hood for 5 minutes at room temperature. 2µg of FLAG-Ligase IV DNA (see section 
3.2) from a successfully transformed bacterial colony was added to the mix, and left for 15 
minutes at room temperature under the fume hood. The mixture was then added to the 
MRC5VA cells, and they were left in an incubator at 37ºC for approximately 48 hours.  
 
3.1.5 Pre-incubation of cells with Sodium Butyrate and Irradiation 
Prior to irradiation, 2mM of Sodium butyrate was added to each flask containing the 
transfected cells. The flasks were then placed in a humidified incubator at 37°C for 6 hours. 
Cells were then trypsinised.  
 
3.1.6 Irradiation of Cells 
 The cells were then irradiated with 30Gy ionising radiation (Caesium137 source). There were 
4 different time points for the cells; No irradiation (0), Irradiated and immediately frozen 
(0IR), Irradiated and frozen after 30 minutes (30), and finally Irradiated and frozen after 1 
hour (1hr). These time points were so that the levels of target protein acetylation could be 
analysed at various time points after DNA damage has occurred. The samples were 
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centrifuged at 15,000 RPM for 3 minutes after their stated time point, washed in PBS, and 
centrifuged once more at 15,000 RPM for 3 minutes before storing at -20ºC.  
 
3.2 Preparation of Flag-tagged Ligase IV DNA for Transfection of Cells 
3.2.1 Restriction Digest 
An insert of Ligase IV DNA in pFASTBAC-HTC vector (Invitrogen) was made available by 
Dr. Boris Kysela. Restriction digests were carried out in order to cut the Ligase IV gene out 
of the pFASTBAC vector, so that it may be inserted into pFLAG-CMV vector (Sigma). 5µg 
of Ligase IV – pFASTBAC DNA was digested in a 1.5ml micro-centrifuge tube with 10 x 
Multicore Buffer (Promega), 1.0µl EcoRI (Promega, 80u/µl), 1.0µl of KpnI (Promega), and 
topped up to 25µl with nuclease free water. pFLAG-CMV vector (Sigma) was also digested 
as described above but with the restriction enzymes EcoRI and KpnI. The two reactions were 
then incubated at 37ºC for 2 hours.  
To ensure digestions were successful, 5x loading dye (50% glycerol, 0.05% bromophenol 
blue) was added to each 1.5ml micro-centrifuge tube, after which 10µl of each was loaded on 
to a 1% agarose gel, containing 0.001% ethidium bromide, along with a 1kb ladder 
(Promega). The gel was run at 150V for 30 minutes. The gel was then visualised under UV 
light and the appropriate bands were then excised from the gel. The DNA was extracted as 
outlined below. 
 
 
 
15 
 
3.2.2 Gel Extraction 
In order to extract the Ligase IV gene fragment, and the digested pFLAG from the agarose 
gel, the QIAquick Gel Extraction kit (Qiagen) was used according to the manufacturer’s 
instructions.  
3.2.3 Ligation 
Ligation reactions were carried out in order to ligate the DNA Ligase IV insert into the 
pFLAG vector. This was done in a 10µl reaction containing 10x buffer (New England 
Biolabs), 1µg pFLAG vector, 3µg Ligase IV insert, 1 unit of T4 DNA ligase (New England 
Biolabs), and topped up with nuclease free water. The reaction was then vortexed briefly, and 
stored at 4ºC.  
3.2.4 Transformation of E.Coli with pFLAG-Lig IV 
One microlitre of DNA was incubated on ice with 10µL competent Escherichia coli in a 
1.5mL microcentrifuge tube for 30 minutes. They were subsequently subjected to a 1 minute 
heat shock at 42°C and returned to ice for 2 minutes. To each microcentrifuge tube, 250µl of 
SOC medium was added and placed in an orbital shaker for 30 minutes at 37°C. Following 
incubation, 125µL of bacterial solution was spread evenly over an LB-Agar plate containing 
100µg/ml ampicillin and incubated at 37°C overnight. Along with pFLAG-DNA Ligase IV 
DNA, a control pUC19 vector and bacteria only control were set up. 
3.2.5 DNA minipreps from bacterial suspensions 
In order to extract the DNA from the transformed bacteria, a Miniprep kit from Roche was 
used according to the manufacturer’s instructions.  
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3.2.6 Identifying Successfully Transformed Bacterial Colonies 
In order to determine which bacterial colonies had been transformed successfully, 15 colonies 
were chosen from the FLAG-DNA Ligase IV plate, and placed into universal tubes 
containing approximately 3ml Luria-Bertani broth. The universal tubes were then shaken 
vigorously on a rotary shaker for 16 hours.  
Double digests were then carried out on each of the FLAG-Ligase IV samples as outlined in 
Section 3.21 i, with the use of the NotI and XbaI restriction enzymes. The digests were 
visualised as outlined in Section 3.21 i, with the successfully transformed bacterial colonies 
showing two separate bands instead of one.  
 
3.3 Protein Extraction and Acetylation 
3.3.1 Protein Extraction 
In order to extract the protein from the irradiated cells (section 3.1.6), the cell pellets were 
resuspended in twice the volume of the cell pellet of phosphoRIPA buffer (50mM Tris/HCl 
pH 7.5, 1mM EGTA, 1mM EDTA, 50mM sodium fluoride, 5mM sodium pyrophosphate, 
1mM sodium orthovanadate, 0.27M sucrose, 1% Triton X-100, 0.1% β-mercaptoethanol, and 
protease inhibitor cocktailand 2mM Sodium Butyrate). The resuspensions were left on ice for 
10 minutes, and were then centrifuged at 17,000RPM for 30 minutes at 4°C. The protein-
containing supernatant was then transferred to a fresh 1.5ml microcentrifuge tube. Following 
this, the concentrations of the proteins were measured, by adding 500µl of water to 500µl of 
Bradford Reagent (Sigma), and 5µl of protein in a cuvette. The absorbance was recorded at 
595nm, using a Genova spectrophotometer against a bovine serum albumin standard. The 
protein samples were then aliquoted into 15µg samples for use in western gels, and 1mg 
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samples for use in immunoprecipitation experiments. The samples were then stored at -80ºC 
for future use. 
3.3.2Western Blotting 
3.3.2.1 SDS-PAGE 
15µg samples of XLF, XRCC4, Ligase IV, and H1-X were denatured by incubating at 100°C 
for 5 minutes in SDS loading buffer (65mM Tris/HCl pH8, 10% (v/v) glycerol, 2.3% (w/v) 
SDS, 0.01 bromophenol blue, 1% DTT). The proteins were then separated by electrophoresis 
on 9% polyacrylamide gels prepared using ProtoGel reagents. This involved preparing a 
resolving gel segment, made from 30% acrylamide Protogel (National Diagnostics), 0.1% 
Sodium Dodecyl Sulphate (SDS), 10% AmoniumPersulphate (0.1g/ml), 
Tetramethylethylenediamine (TEMED) and nuclease free water.  The gel was poured and 
topped up with Isopropanol and left to set. The Isopropanol was washed away and replaced 
with a stacking gel, which was made up of 3% polyacrylamide, 50mM Tris, 0.1% SDS, 10% 
APS, and TEMED; 0.7mm combs were inserted immediately after pouring, and the gel was 
allowed to set. The 15µg protein samples were then loaded onto the gels along with a protein 
ladder, and run in an electrophoresis tank (BIORAD) containing 10x Running Buffer (10x 
Tris-Glycine-SDS PAGE Buffer, National Diagnostics) at 150v for 1 hour.  
3.3.2.2 Transfer from SDS-PAGE to PDVF Membrane 
The resolved proteins from the gel were transferred to a piece of polyvinylidene fluoride 
(PDVF) membrane (Millipore). Prior to transfer, the PDVF membrane was soaked in 100% 
methanol, and then immersed in CAPS buffer (10mM CAPS, pH11, 10% Methanol) along 
with gel and 4 sheets of filter paper in order to perform a wet transfer, using apparatus from 
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Amersham at 0.23mA for 90 minutes at 4°C. The membranes were then blocked in 5% milk 
in PBS and 0.1% Tween overnight at 4°C.  
3.3.2.3 Western Blotting 
Upon completion of transfer to the PDVF membrane, the membrane was inserted into a 50ml 
centrifuge tube which contained 5ml of 5% Milk in PBS/Tween and the appropriate primary 
antibody (See Table 1). It was ensured that the side of the membrane which contained bound 
proteins was facing towards the inside of the tube. The tube was then placed on to a tube 
roller, and was left at room temperature for 1 hour. Following this, the membrane was then 
washed 3 x 10 mins in PBS-Tween, and transferred to fresh tube containing 1% milk in PBS-
Tween solution with the secondary antibody (see table). The membrane was left rolling at 
room temperature for 1 hour. The membrane was then washed again in PBS-Tween for 3 x 
10 mins, after which 1ml of ECLPlus reagent (Amersham) was applied. The membrane was 
wrapped in Saran wrap, and secured into a developing cassette. The membrane was then 
exposed and developed on to X-Ray photographic imaging film (Kodak). The films were 
developed using an X-Ray film developer (Konica Minolta). 
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Primary 
Antibody 
Species Dilution Secondary Antibody Dilution 
Anti-Panacetyl 
Lysine 
Rabbit 1:1000 Goat anti Rabbit-HRP (DAKO) 1:5000 
Anti-H1.X 
(Abcam) 
Rabbit 1:1000 Goat anti Rabbit-HRP (DAKO) 1:5000 
Anti-XLF Rabbit 1:1000 Goat anti Rabbit-HRP (DAKO) 1:5000 
Anti-XRCC4 Rabbit 1:1000 Goat anti Rabbit-HRP (DAKO) 1:5000 
Anti-HDAC3 Mouse 1:1000 Rabbit anti Mouse-HRP (DAKO) 1:5000 
Anti-DNA Ligase 
IV 
Rabbit 1:1000 Goat anti Rabbit-HRP (DAKO) 1:5000 
Anti-FLAG 
(Abcam) 
Mouse 1:1000 Rabbit anti Mouse-HRP (DAKO) 1:5000 
Anti-GFP 
(Abcam) 
Goat 1:1000 Rabbit anti Goat-HRP (DAKO) 1:5000 
Anti-α tublin 
(Abcam) 
Rabbit 1:10,000 Goat anti Rabbit –HRP (DAKO) 1:10,000 
 
3.3.3 In Vitro Acetylation of XLF, XRCC4, LX, and H1-X Proteins 
Protein samples of XLF, Ligase IV- XRCC4 complex (LX) and H1.X were provided by Dr. 
Darren Arbon. A master mix of 2 x reaction buffer was made up, containing 100mMHepes, 
pH8(Sigma), 20% glycerol (Sigma), 2mM Dithiothreitol (DTT) (Sigma), 2mM4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) (Sigma), 10mM Sodium 
Butyrate (Sigma) and nuclease free water. 16 reactions were set up in total, which all 
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contained 1µg of protein, 1µg of a particular histone acetyl transferase (HAT), in addition to 
1µl of acetyl coenzyme A, 15µl of 2 x reaction buffer, and 12µl of nuclease free water in 
order to create a 30µl reaction. The combinations of proteins and HATs were as follows;  
HAT Protein 
PCAF XLF 
PCAF LX 
PCAF H1.X 
P300 XLF 
P300 LX 
P300 H1.X 
CBP XLF 
CBP LX 
CBP H1.X 
GCN5 XLF 
GCN5 LX 
GCN5 H1.X 
 
The reactions were set up in duplicate; half of the reactions contained C14-Acetyl coenzyme 
A, while the other half of the reactions contained non-radioactive Acetyl Coenzyme A. The 
reactions were incubated at 30°C for 1 hour. The samples were then run on a 4-20% gradient 
Mini-Protean precast gel (BioRad) at 150V for 1 hour. The gels were stained overnight with 
Page Blue (Fermentas). Bands which corresponded to XLF, XRCC4, Ligase IV and H1.X 
were excised from the non-radioactive gel, and sent for analysis by mass spectrometry 
(Advanced Mass Spectrometry Facility, University of Birmingham). The radioactive gel was 
placed between a piece of filter paper andSaran wrap after which it was vacuum dried at 80°C 
for 60 minutes on a Gel Master Gel Dryer Vacuum System (Welch).The dried gel was then 
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placed face down onto a storage phosphor screen (Molecular Dynamics), and left to expose 
for 1 week. The results were visualised using a STORM Phosphoimager (Molecular 
Dynamics). 
 
3.3.4In Vivo Acetylation 
In Vivo acetylations of XLF, XRCC4, Ligase IV, and H1.X were examined in order to 
determine whether these proteins were acetylated following exposure to ionizing radiation. 
Cells containing FLAG-tagged XLF and XRCC4 and GFP-tagged H1.X were provided by 
Dr. Darren Arbon. Cells were transfected with Ligase IV as outlined in section 3.1.4.  
 
3.4 Co-Immunoprecipitation  
3.4.1 Immunoprecipitation for GFP-tagged proteins 
In order to carry out the immunoprecipitation, 20µl of protein G slurry was washed twice with 
phosphoripa buffer (excluding protease inhibitor cocktail) (see section 3.3.1) 1mg of protein was 
added to the washed beads, and left for 1 hour with end-over-end rotation at 4°C. The beads were 
then centrifuged at 3000RPM for 2 minutes, after which the supernatant was collected and placed 
into a fresh 1.5ml microcentrifuge tube. At this stage, GFP primary antibody was then added to 
the protein lysates containing GFP-tagged proteins, and they were then subject to end-over-end 
rotation at 4°C overnight. The following day, 10µl of beads were washed twice in phosphoripa 
buffer (excluding protease inhibitor cocktail), after which the lysate-antibody mixture was added, 
and mixed by end-over-end rotation at 4°C for 3 hours. The beads were then pelleted by 
centrifuging at 3000 RPM for 2 minutes, and the supernatant was discarded. 250µl of 
phosphoripa buffer (excluding protease inhibitor cocktail) was used to resuspend the beads, and 
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the mix was the transferred to a spinX centrifuge tube filter (Costar, 0.45µm pore size). The spin 
column was then centrifuged at 7000RPM for 1 minute, and the supernatant was discarded; this 
step was repeated twice more with additional amounts of 250µl phosphoripa buffer for each 
wash. In order to elute the proteins, 35µl of 1x sample buffer (Biorad) was added to the samples, 
and heated to 70°C for 5 minutes, after which the samples were centrifuged for 7000RPM for 1 
minute. The tubes were then stored at -20°C; the results were visualised by running the samples 
on SDS-PAGE gels, as outlined in section 3.3. 
 
3.4.2 Immunoprecipitation for FLAG-tagged proteins 
Prior to use, anti-FLAG agarose beads (Sigma) were rolled at room temperature and vortexed 
gently in order to dislodge the beads. For each immunoprecipitation, 30µl of anti-FLAG 
agarose beads were added to a 1.5ml micro centrifuge tube, and centrifuged at 13,000RPM 
for 1 minute, after which the supernatant was carefully removed and discarded. 1ml of Tris 
was added to each tube, and centrifuged once more at 13,000RPM for 1 minute, and the 
supernatant was discarded. This was repeated 3 times in order to thoroughly wash the beads. 
1mg of the FLAG-tagged proteins was added to the labelled micro centrifuge tubes 
containing the beads, and made up to 1ml with phosphoripa buffer (see section 3.2.1, XI). 
The tubes were then mixed by end-over-end rotation at 4°C for 2 hours. The contents of the 
tubes were then transferred to a spinX centrifuge filter (Costar, 0.45µm pore size), and 
centrifuged at 7000RPM for 1 minute. The flow-through was retained in labelled 1.5ml micro 
centrifuge tubes, and stored at -20°C. Approximately 1ml of Tris buffered saline (1 M Tris pH 
7.5, 5 M NaCl) was added to the spinX filter and was then centrifuged at 7000RPM for 1 
minute. The supernatant was discarded, and the process repeated 3 times. The spinX filter 
was then transferred to a fresh 1.5ml micro centrifuge tube, after which 1 x loading dye was 
added. The tube was then incubated at 100°C for 5 mins, and then centrifuged at 7000RPM 
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or 1 minute, and finally stored at -20°C. To visualise the results, the contents of the tubes 
were then run on western gels (as outlined in section 3.3.2). 
 
4.0 Results 
4.1 In Vitro Acetylation of NHEJ Components 
In order to examine acetylation in vitro, protein samples of XLF, XRCC4, DNA Ligase IV 
and H1.X were individually combined with various HATs, and radioactive C14 acetyl co 
enzyme A. Linker histone H1.X was used as a positive control for acetylation. The HATs 
tested included PCAF, P300, CBP and GCN5 (see section 2.5). The proteins were also tested 
for the basal levels of acetylation which may occur in the absence of a HAT. No acetylation 
was observed for XLF or XRCC4 with any of the HATs tested (data not presented). In 
addition, no acetylation was observed when DNA Ligase IV (labelled LX complex) was 
combined with P300, CBP or GCN5 in vitro, however low levels of acetylation were 
observed for DNA Ligase IV when combined with PCAF (Figure 6). These low levels of 
acetylation could only be observed with 3µg and 4µg of radioactive acetyl co A, suggesting 
that higher levels of acetyl co A are required to acetylate DNA Ligase IV. Strong bands were 
observed when H1.X was acetylated using PCAF, which should be expected. Increasing the 
levels of acetyl co A did not have any significant effects on the levels of acetylation for 
H1.X, showing that acetylation of H1.X readily occurs at lower concentrations of acetyl CoA. 
No acetylation was observed when H1.X was combined with acetyl co A alone, confirming 
that PCAF was responsible for the acetylation observed (Figure 6).  
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Figure 6.In Vitro Acetylation of LX complex and H1.X with PCAF.The LX complex and H1.X were acetylated with 
varying concentrations of radioactive C14Acetyl Coenzyme A; H1.X was used as a positive control for acetylation. 2µg, 3µg 
and 4µg refers to the amount of radioactive acetyl coenzyme A used. Unfortunately, no size markers could be obtained for 
this data.  With regard to LX, very slight bands can be seen at 3µg and 4µg of acetyl coA, marked by the two red arrows; this 
suggests that there is some acetylation occurring. There is a band in the lane for LX alone, however this is suspected to be 
due to slight spill over from the H1.X-PCAF lane, as the band is not the correct size to be LX. H1.X and the LX complex do 
not show any bands in the absence of HATs, and so it can be concluded that any acetylation occurring is due to the presence 
of PCAF. As can be seen, there are three very strong bands which shows H1.X is strongly acetylated in the presence of 
PCAF at varying concentrations of acetyl co.A.  
 
4.1.1 Mass Spectrometry Results 
Due to the fact that no acetylation was observed for XRCC4 and XLF with the use of 
radioactive acetyl co-A, it was thought that perhaps the reason was because the assay was not 
sensitive enough, or needed to be optimised. Therefore in order to ensure accurate results, a 
more sensitive approach was undertaken using mass spectrometry to detect the presence of 
acetylation. By examining acetylation through more than one technique, a greater degree of 
confidence can be applied when making conclusions. XLF, XRCC4, LX and H1.X were 
incubated with non-radioactive acetyl coA and analysed through mass spectrometry in order 
to determine specific levels of acetylation, and to map the particular sites of acetylation 
(Tables 1, 2, 3 and 4).   
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4.1.1a Mass Spectrometry Results for XLF 
 
Table 1: A table to show the sites of acetylation in XLF following incubation with acetyl co A 
and various HATs. The red ticks indicate that acetylation was present at the various lysine residues 
and with the HATs listed. XLF alone lists the sites where XLF is acetylated basally, in the absence of 
HATs. High and low indicate the level of acetylation. As can be seen, the only apparent high 
acetylation was found at lysine 160 with PCAF.. 
 
4.1.1b Mass Spectrometry Results for XRCC4 
Lysine PCAF P300 CBP GCN5 XRCC4 Alone 
102  (low)  (low)  
169 (low) (high)    
187 (high) (med)  (high) (high) 
188 (high) (med) (low) (high) (high) 
197 (low) (high) (high)   
309 (low) (high) (high)   
 
Table 2: A Table to show the sites of acetylation in XRCC4, following incubation with acetyl co 
A. As with Table 1, the red ticks indicate sites of acetylation. Lysines 187 and 188 show high levels of 
acetylation with PCAF, and GCN5, however these sites are also acetylated in XRCC4 alone, and 
therefore acetylation is most likely not due to the presence of the HATs. XRCC4 shows high levels of 
acetylation at lysine 197 and 309 in the presence of P300 and CBP.  
 
4.1.1c Mass Spectrometry Results for Ligase IV  
Lysine PCAF P300 CBP GCN5 Ligase 
IVAlone 
613 (high)  (low) (med) (low) 
 
Table 3: A table to show the sites of acetylation in Ligase IV, following incubation with acetyl 
co A. Ligase IV was found to have only one acetylation site at lysine 613; it is highly acetylated by 
PCAF at this site, and moderately by GCN5. Low basal levels of acetylation were also found in ligase 
IV alone at this site. 
 
 
 
 
Lysine PCAF P300 CBP GCN5 XLF alone 
63  (low)    
160 (high)  (low)   
197 (low) (low) (low)  (low) 
290  (low)    
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4.1.1d Mass Spectrometry Results for H1.X 
 
 
Table 4: A table to show the sites of acetylation in H1.X, following incubation with acetyl co A. 
H1.X is acetylated at many various lysine sites both alone, and in the presence of a variety of HATs. It 
is highly acetylated by CBP at lysine 35, and is highly acetylated at lysines 69, 159 and 160 by P300. 
All other acetylation sites are either moderate or low levels of acetylation, or have basal levels of 
acetylation shown by H1X alone.  
 
4.2 In Vivo Acetylation of NHEJ components 
4.21 In Vivo Acetylation of XLF 
The in vitro acetylation had been tested thoroughly; however in vitro experiments occur 
under a controlled environment, and sometimes do not accurately reflect what occurs in vivo. 
In vivo there are many more variables which cannot be artificially created; for example 
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protein-protein interactions and modifications when in the presence of various cellular 
content may play an essential role which would be neglected in vitro.For these reasons, it was 
necessary to examine the acetylation of XLF within the cell, in vivo. FLAG-tagged XLF was 
over-expressed in the 5VA-MRC cell line. The cells were exposed to 30Gy of radiation, and 
collected at various time points. In order to visualise the presence of acetylation, western 
blots were performed, and blotted with the Panacetyl Lysine (PanacK) antibody; an antibody 
which is specific for any type of acetylation in the sample. The FLAG-XLF showed faint 
bands when blotted with PanacK (figure 7a), however when the FLAG-XLF was 
immunoprecipitated, no reactivity could be observed with the panacK antibody (figure 7b).It 
was suggested that this may have been due to the fact that there was too much unspecific 
binding, and therefore, the IP was then repeated with a high salt wash to remove any 
unwanted and unspecific interactions. The necessary controls were performed to rule out 
false positives and false negatives; the FLAG-tagged XLF was blotted with XLF antibody to 
confirm presence of over-expressed XLF (figure 7a), and blotted with α-FLAG to confirm 
that the XLF was indeed FLAG-tagged (figure 7a). Finally, the western was blotted with α-
tubulin, to ensure all samples tested were of equal loading size (figure 7a). 
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Figure 7.In Vivo Acetylation of XLF and Co-Immunoprecipitation of XLF: A: When blotted with panacK, 
FLAG-tagged XLF showed some faint bands, suggesting low levels of acetylation were present. The FLAG-
tagged XLF was then blotted with the XLF antibody which confirmed the presence of overexpressed XLF with 
4 very clear bands. The FLAG-tagged XLF was shown to be FLAG-tagged by blotting with α-FLAG antibody, 
confirmed by 4 distinct bands. Finally the 4 bands of equal size in the α-tubulin lane show that the FLAG-tagged 
XLF was loaded equally through these experiments. B:Following co-immunoprecipitation of the FLAG-tagged 
XLF, western blots with the PanacK antibody did not show any bands. The IP was repeated with a high salt 
(HS) wash, however upon blotting with the PanacK antibody, no bands were seen. The same blot was blotted 
with α-FLAG antibody to ensure that the IP had been successful, and as can be seen from the row labelled α-
FLAG, bands can be seen for all of the time points of XLF.  
 
 
4.2.1 In Vivo Acetylation of XRCC4 
In order to examine the acetylation of XRCC4 in vivo, FLAG-tagged XRCC4 was over-
expressed in the 5VA-MRC cell line. The cells were exposed to 30Gy of radiation, and 
collected at various time points, as outlined in section 3.1.5 for the in vivo acetylation of 
XLF. The same westerns were performed, using the PanacK antibody to blot for acetylation. 
XRCC4 is known to run around the 55kDa mark, so all bands shown are around this size.  
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Figure 8:  In Vivo Acetylation of XRCC4 and Co-immunoprecipitation of XRCC4When blotted with 
panacK, strong bands were seen around the 55kDa mark, suggesting that XRCC4 was acetylated. The FLAG-
tagged XRCC4 was then blotted with the XRCC4 antibody to show the presence of overexpressed XRCC4, 
which showed 4 very clear bands, as expected. The FLAG-tagged XRCC4 was also blotted with α-FLAG 
antibody to confirm that the XRCC4 was FLAG-tagged, and this was clearly shown by the 4 large bands.  
Finally the FLAG-tagged XRCC4 was blotted with α-tubulin antibody to show equal levels of loading, and this 
was confirmed by the 4 distinct bands of approximately equal sizes. (B)Following Co-IP of the FLAG-tagged 
XRCC4, western blots with the PanacK antibody did not show any bands for the first three time points, however 
at the 1hr time point seemed to show a band. The IP was repeated with a high salt (HS) wash; however upon 
blotting with the PanacK antibody, no bands could be seen. The same blot was blotted with α-FLAG antibody to 
ensure that the IP had been successful, and as can be seen from the row labelled α-FLAG, the bands are all 
clearly FLAG-tagged. 
 
 
4.2.2In VivoAcetylation of Ligase IV 
In order to investigate acetylation in Ligase IV, an experiment was carried out in order to 
express FLAG-tagged Ligase IV in the 5VA-MRC cell line. However, the transfections 
proved to be unsuccessful, and due to time constraints, the establishment of DNA Ligase IV 
stably overexpressing cell lines could not be completed.  
4.3.3 In Vivo Acetylation of H1.X 
Acetylation of H1.X was explored by introducing GFP-tagged H1.X into the 5VAMRC cell 
line, and exposing them to 30Gy of radiation. The cells were then collected at the same time 
points, as outlined in section 3.1.5. Levels of acetylation were determined before and after co-
immunoprecipitation. H1.X is known to run around the 35kDa mark.  
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Figure 9: Co-immunoprecipitation of H1.X Following co-IP of the GFP tagged H1.X, western blots with the 
PanacK antibody did not show any bands. This was a particularly odd result, as H1.X is normally used as a 
positive control for acetylation. The cells successfully overexpressed H1.X, as 4 clear bands were observed 
when blotted with H1.X antibody. In addition, it was confirmed that H1.X was GFP-tagged, as 4 distinct bands 
were seen when blotted with GFP antibody.  
  
5.0 Discussion 
5.1 In Vitro Acetylation 
In order to investigate the levels of acetylation in XLF, XRCC4, DNA Ligase IV and H1.X in 
response to DNA damage, in vitro assays were carried out. It was important to establish the 
degree of acetylation for these components of the NHEJ pathway primarily in vitro due to the 
fact that the complexities of interactions which occur within a cellular environment involve 
numerous variants which may affect acetylation. For this reason, if only the in vivo effects of 
acetylation were investigated, it would be difficult to conclude with confidence that the 
acetylation was occurring as a direct result of the various HATs tested. Therefore, in order to 
simplify the reaction, and reduce the number of external variables within the experiment, the 
levels of acetylation were investigated through the use of radioactive acetyl coA and samples 
of XLF, XRCC4, DNA Ligase IV and H1.X in protein form.  
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Upon completion of the in vitro assays with, it was found that no acetylation could be 
observed for XLF or XRCC4 alone or in the presence of any HAT tested. It was thought that 
perhaps the proteins had not been given a sufficient incubation period in the presence of 
acetyl co-A and the HATs, however it seemed that additional time had no effect on the levels 
of acetylation observed. These negative results do not necessarily mean that these 
components are not acetylated in vitro. For example, the process of incubating the proteins in 
the presence of radioactive acetyl co A and the subsequent exposure on to the radioactive 
plates may not pick up on particularly low levels of acetylation. In addition, the proteins were 
only tested in the presence of 2µg of acetyl co-A, and this may not have been of a sufficient 
concentration to acetylate the proteins to a detectable degree. An example of this can be 
found in the in vitro acetylation of the LX complex, which primarily did not show any 
acetylation, however when tested in the presence of varying amounts of acetyl co-A, LX 
seemed to show low levels of acetylation only with 3µg and 4µg of acetyl co-A, and not with 
2µg as the other proteins were tested with (figure 6). For this reason, it would be beneficial to 
examine the in vitro levels of acetylation of XLF and XRCC4 in the presence of higher 
concentrations of acetyl co-A.  
H1.X was used as a positive control for acetylation, and showed positive results when tested 
in the same manner as the other proteins. However, H1.X is known to be heavily acetylated 
in the presence of HATs, and therefore may show acetylation at much lower concentrations 
of acetyl co A. The LX complex showed faint bands in the presence of 3µg and 4µg of acetyl 
co-A, as can be observed in figure 6. This suggests that perhaps increasing the concentration 
of acetyl co-A may lead to higher levels of acetylation.  
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5.2 Mass Spectrometry Analysis of in vitro Acetylation  
Due to the fact that previous methods to observe in vitro acetylation were not as successful as 
previously hoped, a more sensitive approach was employed in order to determine whether 
acetylation could be observed. The proteins were incubated with non-radioactive acetyl co-A, 
and then analysed through mass spectrometry.  
 
5.2.1 XLF 
XLF showed low levels of acetylation in the presence of P300 and CBP, but not with GCN5. 
XLF did show that at lysine 160, there were high levels of acetylation in the presence of 
PCAF; suggesting that XLF is in fact acetylated in vitro, but perhaps not to the degree that 
may have been detectable through the previous method. The mass spectrometry analysis also 
showed a low basal level of acetylation in XLF at lysine residue 197 (table 1), however, it is 
possible that a certain degree of acetylation may arise as a result of overexpressing the 
protein. For example, in Baculovirus expression systems, post-translational modifications 
may occur, and similarly this may happen also through the process of overexpressing proteins 
in mammalian cells. Therefore, although there is supposedly a low basal level of acetylation, 
it cannot be said with confidence that this occurs in vivo. 
 
5.2.2 XRCC4 
XRCC4 showed high levels of acetylation in the presence of both PCAF and GCN5 (table 2). 
However, XRCC4 was also shown to be highly acetylated alone at these sites, and therefore it 
is difficult to know whether the acetylation is occurring as a result of the presence of the 
HAT. XRCC4 was also shown to have high levels of acetylation at lysines 197 and 309 in the 
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presence of both P300 and CBP. Furthermore, XRCC4 did not seem to be acetylated at these 
sites when no HAT was present. This suggests that XRCC4 can be acetylated in vitro and 
may therefore become acetylated in response to DNA damage by P300 and CBP in vivo.  
 
5.2.3 DNA Ligase IV 
When DNA Ligase IV was examined for in vitro acetylation through mass spectrometry 
analysis, it was found that there was only 1 lysine residue which was acetylated. Lysine 
residue 613 was shown to be highly acetylated by PCAF, moderately by GCN5, and only 
slightly by CBP. However, low levels of acetylation were also present in DNA ligase IV 
alone. This may suggest that the acetylation is not as a result of being in the presence of the 
HATs. However, due to the fact that there are only low levels of acetylation in the absence of 
a HAT, and high acetylation in the presence of PCAF, it is possible that DNA ligase IV is 
basally acetylated to a low degree, but may become hyper-acetylated in the presence of 
PCAF.  
 
5.3In Vivo Acetylation 
The in vitro results received for XLF, XRCC4 and LX were suggestive, but not conclusive. 
There are many disadvantages to testing in vitro including the fact that it can be difficult to 
extrapolate results to relate to the endogenous interactions and the biology of the whole 
organism. Therefore it was important to test levels of acetylation in response to DNA damage 
in vivo.  
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5.3.1 XLF Acetylation In Vivo 
MRC-5VA cells which were cultured to overexpress FLAG-XLF were exposed to 30Gy of 
radiation, and were collected at various time points in order to assess levels of acetylation in 
response to DNA damage. When blotted with PanacK, faint bands correlating to XLF were 
observed, suggesting that there was some acetylation present. This was confirmed by 
ensuring that FLAG was present. The band for 0ir seemed to be slightly darker in comparison 
to the 30min and 1hr time points, suggesting that XLF is acetylated immediately in response 
to DNA damage, and may become slightly deacetylated with time. However, the cells that 
had not been irradiated were also shown to be acetylated. It therefore is questionable as to 
whether the acetylation is as a result of exposure to DNA damage or not.  
Immunoprecipitations were carried out to further confirm whether acetylation was present. 
However, no reactivity could be observed with the panacK antibody (figure 7b). It is possible 
that this was due to a high level of unspecific binding and background interactions. The IP 
was repeated with a high salt wash to remove any unspecific binding, but it appeared that this 
also removed the interactions of interest. Therefore the IP results were inconclusive.  
 
5.3.2 XRCC4 Acetylation In Vivo 
Cells which overexpressed FLAG-XRCC4 were subject to the same procedures as outlined 
for XLF in order to determine levels of acetylation following DNA damage. When blotted 
with the panacK antibody, there were 4 strong bands around the 55kDa mark, suggesting that 
there was acetylation present at all 3 time points. There also appeared to be acetylation in the 
sample that had not been exposed to irradiation, suggesting that like XLF, XRCC4 also had a 
basal amount of acetylation present prior to DNA damage. However, the bands seemed to 
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darken at the 0ir time point, which implies that XRCC4 undergoes further acetylation in 
response to DNA damage, as with XLF. This was then examined through 
immunoprecipitation, where conversely no bands were observed for any time point, except 
for a very faint band at 1hr. This seems feasible, however the results from the IP were very 
dirty, and therefore to confirm this with confidence, a cleaner IP would be required. High salt 
washes were performed in order to attempt to tidy up the results, however as with XLF, the 
washes appeared to remove all interactions of interest.  
 
5.3.3 H1.X Acetylation In Vivo 
H1.X is a histone known to undergo high levels of acetylation and deacetylation, and was 
therefore used as a positive control for acetylation. This was confirmed by the in vitro results, 
however when investigated in vivo, the results unusually showed a negative result for 
acetylation. The IP was repeated several times; however the negative result remained the 
same. Clear bands were seen at the 17kDa mark, however due to the fact that H1.X usually 
runs at the 35kDa mark, it was concluded that these bands did not correlate to H1.X.  
 
5.4 Final Conclusions 
After careful analysis of all in vitro and in vivo results, there can be several conclusions 
made, and evidence has been provded which would suggest that further research into this area 
would provide interesting results.  
Mass spectrometry analysis of XLF in vitro showed high levels of acetylation at one lysine 
residue in the presence of PCAF. In addition, in vivo studies showed that following DNA 
damage, XLF presented a positive result for acetylation, particularly at 0ir; immediately 
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following damage. These results imply that following DNA damage, XLF may become 
acetylated at lysine 160 by PCAF. The implications this may have with regard to the NHEJ 
pathway are elusive, however with additional verification, this provides reason to further 
investigate whether this step is important for the correct function of the DNA damage 
response. It must not be ignored however, that acetylation was observed in the absence of 
DNA damage, both in the mass spectrometry results, and in the in vivo result, which implies 
that perhaps XLF is acetylated to a low degree under normal conditions, but it does not rule 
out the possibility that it may become further acetylated in the presence of DNA damage. 
Similarly, XRCC4 showed comparable results when examined in vitro and in vivo for 
acetylation in that high levels of acetylation were reported from the mass spectrometry 
analysis at two lysine residues by CBP and P300. In Vivo results showed that XRCC4 was 
acetylated at all 3 time points following irradiation, but also when it had not been irradiated. 
Like XLF, XRCC4 showed a slightly darker band at 0ir when compared to 0, suggesting that 
it has a basal level of acetylation under normal physiological conditions, and may become 
hyper-acetylated in response to DNA damage. This evidence implies that perhaps the post-
translational modifications of XLF and XRCC4 in response to DNA damage may have a 
similar role in ensuring successful repair through NHEJ. The immunoprecipitation results 
were not successful in providing any clear conclusions;however after observing all results 
received from this procedure, it seems that the results received are unreliable, as H1.X 
showed a negative result for acetylation.   
Unfortunately, due to time constraints, it was not possible to examine the acetylation of DNA 
Ligase IV in response to DNA damage. However the in vitro results suggest that DNA Ligase 
IV can be highly acetylated by PCAF at lysine residue 613. As with XLF and XRCC4, 
acetylation was found to be present in the protein in the absence of any HATs, and therefore 
it seems that under normal conditions, it is possible that DNA Ligase IV is similar to XRCC4 
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and XLF in that it has a basal level of acetylation, and may become hyper-acetylated at lysine 
residue 613 by PCAF in response to DNA damage. DNA Ligase IV is known to form a 
heterodimer with XRCC4 and to play an essential role in the NHEJ pathway, and therefore it 
does not seem unreasonable to hypothesize that the levels of acetylation of DNA Ligase IV 
may mimic the levels of acetylation seen in XRCC4.  
In conclusion, in order to make firm conclusions regarding the acetylation of these 
components of the NHEJ pathway, it is important that a more specific antibody is used.The 
panacK antibody was not ideal, and often produced dirty western blots with high levels of 
unspecific binding. This made it difficult to confirm findings, and therefore with a more 
specific antibody for acetylation, it may be possible to generate more reliable results. In 
addition, as the immunoprecipitation reactions were unsuccessful in providing any reliable 
results, the method used in this project should be reviewed in order to optimise the reactions, 
or to identify the reason for their failure. There is sufficient evidence provided in this study to 
suggest that DNA Ligase IV is acetylated in response to DNA damage, and therefore this 
should be examined in the same manner as XLF and XRCC4; however it is hypothesiezed, 
that DNA Ligase IV will have similar results to that of XLF and XRCC4, particularly as 
DNA Ligase IV forms a heterodimer with XRCC4. Finally, the evidence provided implies 
that these components of the NHEJ pathway are acetylated under normal physiological 
conditions, but may undergo further acetylation in response to DNA damage and this may 
have an important role to ensure successful repair of damaged DNA.  
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1.0 Abstract 
 
Exome sequencing combined with techniques such as autozygosity mapping provides a 
useful method to examine variants for autosomal recessive diseases. This approach has been 
used to investigate and identify the causal variants in two Pakistani families with Ichthyosis 
and two Israeli-Arab families with Cerebral palsy. 
Autosomal Recessive Congenital Ichthyosis (ARCI) is a rare and genetically heterogeneous 
disorder characterized by hyperkeratosis in addition to dry, scaly skin. Exome sequencing 
data for two affected individuals from two Pakistani families were analysed. Candidate 
variants were screened for in several additional members from each of the families to 
determine if the mutation segregated. It was found that a mutation in ABCA12 segregated in 
all affected members across both families. Linkage analysis studies performed suggested that 
the variant had originated from a common ancestor, which implied that the families may have 
been distantly related.  
Cerebral palsy is characterised by non-progressive abnormalities in posture and motor 
function as a result of a defect in the development of the nervous system. Exome sequencing 
data was provided for two individuals from two Israeli-Arab families with Cerebral palsy. A 
novel variant found in HPDL is believed to play a causative role in the Cerebral palsy 
investigated; however this gene has not been well characterised and so collecting evidence to 
support this theory will be challenging. The successful identification of disease genes and the 
improved understanding of their methods of pathogenesis, new potential targets may be 
discovered through which new treatments, therapies, and methods of diagnosis may be 
developed.  
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2.0 Introduction 
 
2.1 Consanguinity and Recessive Disease 
The concept of consanguinity refers to a union in which the couple are known to share genes 
inherited from one or more common ancestors, and consequently, their offspring will contain 
segments of their genome which are homozygous (1).  Many major populations have a 
preference towards close-kin marriages due to the social and economic advantages 
associated; this is particularly true in various parts of India, Pakistan and in many Muslim 
countries (1). An additional factor which exerts a major influence on the preference for a 
consanguineous relationship is religion; which is demonstrated by the geographical 
distribution of consanguinity (figure 1).  For example, in most Muslim countries from the 
Middle East and Pakistan, over 50% of the marriages are said to be consanguineous (2).  
Recent studies have shown that approximately 10.4% of the 6.7 billion global population are 
related as second cousins or closer (3).  
 
 
 
 
 
 
 
 
Figure 1. Global Distribution of Marriages between related couples as second cousins or Closer 
from Bittles AH et al (2009) 
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There are many adverse genetic implications associated with a consanguineous marriage, 
particularly when assessing the proportion of identical gene pairs which will be present in the 
progeny, as they are inherited from a common ancestor (1). The majority of consanguineous 
marriages are between first cousins, which results in the sharing of approximately 12.5% of 
genes (4). As a result, the children will be homozygous for 6.25% of gene loci, and thus the 
coefficient of inbreeding (F) is equal to 0.0625 (4). The clinical consequences of this are that 
in consanguineous populations, it is expected that there will be an increased incidence of 
autosomal recessive disease (8). According to Bittles et al. (2007), the genetic risk of an 
autosomal recessive disorder being expressed in the offspring of a consanguineous marriage 
is inversely proportional to the frequency of the disease allele within the total gene pool (5). 
In addition, longer histories of consanguinity within a family are expected to exhibit a much 
higher degree of homozygosity in the offspring, in comparison to a single case of 
consanguinity. For this reason, the risk of acquiring a recessive disease also increases with 
the length of the history of consanguinity within a given family (8). 
 Many rare disease genes have been identified, and their chromosomal locations have been 
mapped through the investigation of consanguineous families with multiple affected 
individuals (5). Recent advances in technological abilities to rapidly sequence the whole 
genome with high-throughput have provided a considerable opportunity to discover and 
analyse various genotype-phenotype correlations (5,6).  
 
2.2 Autozygosity Mapping   
The term ‘autozygosity’ refers to the situation in which two alleles at a particular locus 
originate from a common ancestor as a result of a consanguineous mating. It is not 
uncommon for the progeny of a close-kin marriage to acquire an autosomal recessive 
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disorder as a result of the inheritance of two disease alleles which are identical by descent 
(IBD) (figure 2). To investigate the genotypes of such individuals, autozygosity mapping has 
become a useful tool, which makes use of the inbreeding coefficient to search for an 
autozygous region within the genome of the affected individuals, and so provides an 
alternative method to identify disease associated single nucleotide polymorphisms (SNPs) 
(7). 
The use of autozygosity mapping to characterise and identify genes in autosomal recessive 
disorders remains a powerful and effective technique with which information may be 
generated in order to facilitate the diagnosis of patients and to indicate the potential 
functional role of the disease gene (7).  
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Figure 2. A diagram to show the principal of autozygosity in consanguineous families The 
recessive mutation (RM) is shown in red. Through the pattern of random inheritance, the mutation is 
passed on through the generations. The offspring of a consanguineous marriage can inherit two 
disease alleles which have originated from a common ancestor, thereby causing an autosomal 
recessive disorder. 
 
2.3 Sequencing and Exome Analysis 
 
The term ‘Genomics’ refers to the systematic study on a whole-genome scale for the 
identification of genetic contributions to human conditions (9). Following the completion of 
the human genome project in 2001, the field of genomics has been advancing exponentially, 
as the costs are decreasing, while the ability to sequence multiple reads in parallel at high-
throughput is continually progressing.  For example, in 2001, the first human genome was 
sequenced at a cost of $2.7 billion, and took 13 years to complete (9). Today, an entire human 
6 
 
genome can be sequenced over the course of a few days, and is expected to cost 
approximately $10,000 in the near future (9).  These advances have instigated a paradigm 
shift in the approaches with which both rare and common diseases are investigated (10).  
Despite the technological advances, and the on-going decline in the cost of sequencing, 
Whole genome sequencing (WGS) still remains prohibitively expensive to use frequently 
(10). Although WGS provides the highest sensitivity and accuracy when genotyping an 
individual, there is a considerable amount of redundancy to this method. The expenses 
associated with WGS and the vast amount of data provided could be considered to be in 
excess of what is required to generate the same conclusion.  For this reason, employing 
targeted sequencing approaches as opposed to sequencing the entire genome of an individual 
may provide higher sequence coverage of the regions of interest, at a fraction of the cost (9).  
 
2.3.1 Exome Sequencing 
Whole exome sequencing provides a less expensive alternative to WGS, involving the 
sequencing of only the protein-coding genes as opposed to the entire genome of an 
individual. The protein-coding genes make up approximately 1% of the human genome, 
however despite this, studies suggest that the protein-coding genes may harbour up to 85% of 
harmful mutations with large effects on disease-associated traits (10). For this reason, 
although exome sequencing does not screen the whole genome, current research suggests that 
there is a high probability that a causative mutation may be found within the coding region of 
the genome. 
Exome sequencing is performed by hybridizing genomic DNA to oligonucleotide probes 
which cover specific regions of the human exome (24). These particular regions are then 
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sequenced at high throughput, using second generation sequencing technologies. The three 
major platforms used include one by Agilent, one by Roche/Nimblegen and finally another 
platform designed by Illumina. The main principle remains the same across all three 
platforms, in that they make use of biotinilated oligonucleotide probes which are designed to 
be complementary to the exome targets in question (24). 
 The success of exome sequencing depends on several factors; firstly it depends on the 
mutation being present within the region of the genome examined. In addition, should the 
mutation be found, successful conclusions depend on the ability to identify the gene as 
harbouring the causative variant, and having sufficient sample sizes and evidence to eliminate 
the possibility of it being a random variation (11). The identification of a gene which 
harbours a mutation for a given disease is important in order to understand the genetic basis 
of the disorder. Through understanding and appreciating the role of a mutation in the 
acquisition of a particular disease, knowledge may be applied to carry out further research in 
order to develop potential therapies and treatments.  
 
2.4 Main Aim of Project 
The main aim of this project is to use whole exome sequencing data to attempt to find and 
identify the causative mutation for several autosomal recessive diseases. Through PCR and 
Sanger sequencing, this project aims to show that the mutation identified segregates with all 
tested family members, and that the mutation is not present in the general population. Once 
identified, to further confirm that the mutation is the causative factor for the disease, 
microsatellite markers will be used to confirm linkage with the mutation across the family 
which is therefore consistent with the hypothesis. 
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3.0 Materials and Methods 
3.1 Patient Data 
Consanguineous families from Pakistan and Saudi Arabia were examined and analysed in this 
project for Ichthyosis and Cerebral palsy. Permission was received from all of the families 
studied. For each of the families, extracted DNA was supplied by Dr. Neil Morgan, and made 
up to a concentration of 20ng/µl for all affected, and the majority of unaffected family 
members.  
3.2 Chemicals and Reagents  
 
10 x TBE Buffer (Tris-borate/EDTA) 
Agarose 
Ethanol 
Ethidium Bromide 
Genescan-500 LIZ Size Standard 
Hi-Di Formamide 
PCR Reagents 
Primers 
1 kb DNA ladder (1µg/µl) 
Biomix Red 
GC Rich Solution 
Solutions for Sequencing Reactions 
BigDye Terminator  
Big Dye Sequencing Buffer 
 
National Diagnostics 
Invitrogen 
Fischer Scientific 
Sigma 
Applied Biosystems 
Applied Biosystems 
 
Sigma 
Invitrogen 
Bioline 
Roche 
 
Applied Biosystems 
Applied Biosystems 
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30 Cycles 
3.3 Polymerase Chain Reaction (PCR) 
For each gene, polymerase chain reaction (PCR) was carried out, primers were designed 
either manually (‘by eye’), or by using the program exonprimer, 
(http://ihg.gsf.de/ihg/ExonPrimer.html). 
3.1.3a Standard PCR amplification for Candidate Genes 
PCR amplifications were carried out in 25µl reactions containing 20ng of DNA, 1.5mM Biomix 
Red, and 5pmol of both the forward and reverse primers. To ensure contents were thoroughly mixed, 
the microtitre plate was spun in a centrifuge at 1000 RPM for 30 seconds. For each PCR carried out, a 
negative control was included which involved the addition of water instead of DNA to ensure that the 
samples were not contaminated. Some primers used in the PCR amplifications had a high GC content, 
and therefore to optimise these reactions, 0.5mM GC Rich Solution was used. The stages of the PCR 
cycle can be found in table 1.  
 
Temperature Time Purpose 
94°C 3 mins Initial Denaturation 
94°C 1 min Melting 
60°C 1 min Annealing 
72°C 1 min Extension 
72°C 5 mins Final Extension 
 
Table 1. The Stages of a Standard PCR Cycle  
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30 Cycles 
3.1.3b Analysis of Products from Standard PCR Cycle 
The results of the PCR amplification reactions were run on 1% (w/v) Agarose gels containing 
Ethidium Bromide. 5µl of 1 kb ladder size marker was loaded alongside the samples to allow 
product sizes to be identified. 5µl of PCR product was then loaded and the DNA was then 
separated through electrophoresis in 1 X TBE buffer at 150V. The PCR products were then 
visualised using a UV light transilluminator.  
 
3.1.3c PCR Amplification of Microsatellite Markers 
PCR amplifications of microsatellite markers were routinely carried out in 10µl reactions 
which contained 20ng of genomic DNA, as well as 5mM Biomix Red and 2.0 pmol of the 
forward and reverse primers. The microtitre plate was then placed into the PCR machine, 
where the following PCR stages were carried out (table 2).  
 
Temperature Time Purpose 
95°C 5 mins Initial Denaturation 
95°C 30 secs Melting 
55°C 30 secs Annealing 
72°C 30 secs Extension 
72°C 5 mins Final Extension 
 
Table 2: PCR stages for the amplification of Microsatellite Markers 
 
 
28 cycles 
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3.1.3d Analysis of Microsatellite Marker Data 
In order to analyse the microsatellite data, the samples were run on the ABI 3730 DNA 
Analyzer. Prior to this, the markers were diluted 1 in 15 with dH20 after which 1.5µl of the 
diluted product was added to 10µl of Hi-Di Formamide and 0.04µl Genescan-500 LIZ size 
standard. The results and product sizes were analysed using Genemapper v3.0 software 
(Applied Biosystems).  
 
3.4 Sequencing of PCR Products 
3.1.4a PcR product clean-up 
An equal volume of microCLEAN was added to 2.4µl of PCR product obtained following 
section 3.1.3a in a microtitre plate, and centrifuged for 40 minutes at 4000RPM. Following 
this, the supernatant was removed by inverting the plate on to a paper towel, and then 
spinning in the centrifuge at 500RPM for 30 seconds.  
 
3.1.4b Sequencing Reactions 
To each well, a sequencing buffer was added which included 2µl Big Dye Sequencing buffer 
(Applied Biosystems), 0.5µl Big Dye reaction mix (Applied Biosystems) and 5.5µl dH20. 
2pmol/µl of the appropriate forward or reverse primer was then added, and was put into the 
PCR machine with cycling conditions of: 
• 96oC 30 seconds 
• 50 oC 15 seconds       x 30 
• 60 oC 4 minutes 
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3.1.4c Sequencing Reactions Clean-up 
The sequencing reaction was then cleaned up by adding 2µl of EDTA (0.125M) to each well 
along with 30µl of 100% Ethanol, and spinning at 2000 RPM for 20 minutes. The supernatant 
was removed again as before, by blotting on a paper towel, and spinning upside down for 30 
seconds at 500 RPM. The pellet was left to dry for 5 minutes before adding 90µl of 70% 
Ethanol to each well. The plate was then spun at 2000 RPM for 10 minutes, after which the 
supernatant was removed as outlined earlier. Finally the pellet was resuspended in 10µl of 
Hi-Di Formamide, and denatured at 95°C for 3 minutes, and snap chilled on ice for 5 
minutes. The microtitre plate containing the samples was then loaded on to an ABI Prism 
3700 Sequencer by Dr. Dean Gentle. The resulting DNA sequences were analysed with 
BioEdit Sequence Alignment Editor, or ChromasLite.  
 
3.5 Analysis of Whole Sequencing Data 
Whole Exome Sequencing data was provided by Prof. Eamonn Maher in collaboration with a 
group in Guy’s Hospital, London. For each disease studied, the 25,000 variants received from 
the exome sequencing data were screened and analysed in order to exclude those which were 
present in the dbSNP131 or the 1000 Genomes project. In addition, synonymous variants 
were excluded as they do not alter the protein encoded.On average, the data was narrowed 
down from approximately 25,000 variants to 50 potential candidate variants. Candidate genes 
for Ichthyosis were identified through the observation that ABCA12 and ALOXE3 were 
already known to be associated with the disease. Whereas the candidate genes for the 
Cerebral palsy family were prioritised through linkage data provided from earlier research by 
Dr. Neil Morgan.  
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3.6 Screening Controls for Candidate Gene 
To ensure that sequence variants were not present in the general population, the variants were 
screened in a panel of control samples of either Asian or Saudi Arabian controls. The controls 
tested depended on the population from which the variant was found. The control DNA 
samples were provided by the West Midlands Regional Genetics Laboratory.  
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4.0 Results 
4.1 Ichthyosis 
Autosomal Recessive Congenital Ichthyosis (ARCI) is a rare and genetically heterogeneous 
disorder characterized by hyperkeratosis in addition to dry, scaly skin. ARCI consists of three 
major subtypes, among which the range of clinical features and severity of disease varies.  
The subtypes include Harlequin Ichthyosis (HI), which is the most severe and devastating 
form of Ichthyosis, and is often fatal in the majority of affected neonates (12). Lamellar 
Ichthyosis (LI) and Congenital Ichthyosiform erythroderma (CIE) make up the further two 
subtypes, and while they are devastating, they are not as severe as HI.  The HI patients 
present with critical and significant clinical features at birth, including severe ectropion, 
eclabium and flattened ears, in addition to large plate-like scales over the entire body (13,14). 
The patients who suffer from CIE on the other hand exhibit fine scales in addition to variable 
erythroderma, while LI patients show less severe erythroderma, but have thick, dark scales 
over the entire body (13,14).  
 
4.1.1 Clinical Features of Two Families with Ichthyosis 
The affected individuals of family 1 presented with fine white scales over the entire body, in 
addition to dry skin and hyperkeratosis of the hands, feet, elbows and knees (figure 3). The 
hair of the patients seemed very dry, brittle and thin. Deep pits were present in the toenails, 
and they seemed to be dystrophic. The individuals could not sweat, and therefore were heat 
intolerant. 
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Figure 3. Clinical Features for Several Patients from Family 1 with Ichthyosis: (A) Proband from 
family 1 shows dry, cracked skin and hyperkeratosis on the bottom of the feet. (B) Another member 
of family 1 exhibits fine, white scales in addition to erythroderma over entire body. (C) Severe 
hyperlinear palms on an additional member of family 
 
The affected individuals in family 2 similarly showed fine white scales over the entire body 
in addition to rough, dry skin (figure 4). The patients all had generalized pruritis and 
exhibited erythematous and exczematous lesions. All patients had hypohidrosis, and as a 
result, suffered from severe heat intolerance. Despite their conditions, all patients had normal 
mental health. 
 
 
 
 
 
 
 
 
 
Figure 4. Clinical Features for Proband from Family 2  
(A) The patient exhibits 
yellowish adherent scales and 
dry skin on the scalp. In 
addition, the patient displays 
fine white scales over the entire 
body and erythroderma. 
Hyperkeratosis can be observed 
on the feet, knees and elbows 
(B,C). The patient and the other 
affected individuals in the 
family all have hypohidrosis 
and have severe heat 
intolerance. The affected 
patients in family 2 also have 
difficulty breathing and allergic 
rhinitis. 
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4.1.2 Methods 
 
4.1.2a Patient Information 
Two consanguineous Asian families from the remote area of Sindh, a province within 
Pakistan, were ascertained and provided samples to be studied by King’s College London. 
The anonymous pedigrees of the families can be found in section 4.1.2b. For both families, 
DNA was available for most of the affected individuals, at least one of their parents, and 
some unaffected individuals. The range of clinical symptoms varied among the affected 
individuals, however all presented with dry, scaly skin and hyperkeratosis to the elbows, 
knees, feet and hands.  
4.1.2b Pedigree Information for Families 
Family 1: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.The pedigree for family 1.The affected individuals, shaded in black. The Proband is 
marked ICH107. 
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The pedigree for family two shows the three affected individuals in black. The Proband is 
shown at ICH204. 
 
4.1.2d Mutation Analysis of Candidate Genes 
Primers were designed for ABCA12 using the UCSC genome browser to view the full 
sequence, and identify the location of the mutation. Primers were designed to flank either side 
of the coding exon harbouring the mutation. The program ExonPrimer(http://ihg2.helmholtz-
muenchen.de/ihg/ExonPrimer.html) was used to facilitate the design of the primers, which 
were ordered from Sigma Aldrich. 
These primers were used to amplify regions of interest of ABCA12 from DNA of the two 
families (see methods section 3.1.3) 
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4.1.2e Markers Analysed in the Families  
Microsatellite markers flankingABCA12 were used to establish linkage within the two 
families. The following microsatellite markers were chosen: D2S2944, D2S2382, D2S164 
and D2S434. PCR reactions were carried out and analysed, as outlined in methods section 
3.1.3.  
 
4.1.3 Results 
4.1.3a Analysis of Exome Sequencing Data 
 
Whole exome sequencing data was provided for the probands, ICH107 and ICH204. Through 
process of elimination, the novel and non-synonymous changes were identified. This lowered 
the number of candidate variants from the original 29,403 to 51 variants in family 1, and was 
reduced from 29,526 down to 51 variants in family 2.  
There are 6 genes currently known to be associated with Ichthyosis; ALOXE3, ALOX12B, 
TGM1, CYP4F22, NIPAL4 and ABCA12. Upon analysing the exome sequencing data for both 
families, it was noticed that two genes had already been described in current literature, and had been 
shown to play a causative role in the disorder. Both family 1 and family 2, although thought to be 
unrelated, carried the same mutation in 1 particular gene; ABCA12. For this reason, ABCA12 was 
identified as the primary candidate gene. 
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4.1.3b Analysis of Sequence Data  
Following the sequencing of ABCA12 with the DNA from the individuals, the 
electropherograms were analysed to determine whether the mutation segregated in the 
families. It was found that the affected individuals all showed a homozygous change for the 
mutation, while all parents consistently showed that they were heterozygous carriers for the 
mutation. Furthermore, all controls screened for the mutation showed that they all had the 
wild-type genotype (figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Sequence Analysis of Ichthyosis Patients. 
 
(A) Reverse sequence data for the Proband in family 
1 shows a homozygous change, and shows the parent 
to be a heterozygous carrier for the mutation. (B) 
The sequence data for family 2 shows also the 
heterozygous genotype of one of the parents. (C) 
Control DNA sample from Pakistan showed that the 
wildtype genotype was present. This was true of all 
controls examined.  
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4.1.3c Autozygosity Mapping  
In order to investigate whether the two families sharing the identical mutation in the ABCA12 
gene also shared a common haplotype, autozygosity mapping using microsatellite markers 
was carried out. The two families with Ichthyosis from Pakistan were analysed with 
microsatellite markers flanking ABCA12. The markers included D2S2944, D2S2382, 
D2S164, and D2S434.  
 
 
 
Figure 8.Autozygosity mapping in Family 1 to show linkage of the mutation within the 
family.The microsatellite markers used are shown in order in bold writing; the alleles for 
each individual tested are shown in the same order as the markers. The affected individuals 
show homozygosity for the mutation, and the parents clearly show that they are heterozygous 
for the mutation. It should be noted that individuals ICH110 and ICH112 show a different 
haplotype to the other affected individuals in the family. This is most likely due to a 
recombination event between the ABCA12 and DSS164.  
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Figure 9:Autozygosity Mapping of Family 2. The microsatellite markers used are shown in 
bold writing; the alleles for each individual tested are shown in the same order as the 
markers. Upon observation of this map, and the map of family 1, it seems that the mutation 
segregates, and is clearly linked between affected individuals.  
 
 
  Family 1 Family 2 
Marker Physical 
Location 
(Mb) 
ICH103 ICH110 ICH203 ICH204 ICH209 
D2S2944 21.4 107 107 107 107 107 
ABCA12 21.5      
D2S2382 21.6 329 -- 306 306 306 
D2S164 21.7 274 284 -- 274 274 
 
Table 3.Haplotype Analysis in Pakistani Patients Homozygous for the 1559 G>V mutation 
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4.1.4 Discussion of Ichthyosis and ABCA12 
To date, several genes have been shown to be associated with Ichthyosis, including ALOXE3, 
ALOX12B, TGM1, CYP4F22, NIPAL4 and ABCA12 (2,4). Mutations in the ABCA12 gene have been 
identified in various cases of all three subtypes of Autosomal Recessive Congenital Ichthyosis. The 
resulting defect in the ABCA12 protein is thought to play a causative role in the development of the 
disease in these particular cases. 
 
4.1.4aABCA12 and the ABCA12 Protein 
ATP-binding cassette sub-family A member 12 is a protein that is encoded by the ABCA12 
gene. ABCA12 is part of the ATP-binding cassette family, which are involved in the 
regulation of the transport of certain molecules across cell membranes. ABCA12 has been 
shown to be expressed in various cells and tissues, including skin cells, placenta, lung, 
stomach and liver (17). Interestingly, normal function of ABCA12 has been reported to be 
essential for the development of the epidermis, and therefore mutations in this gene may 
result in skin disorders, such as Ichthyosis (17). The function of ABCA12remains relatively 
elusive; however it is thought that its main role is involved with the transportation of lipids in 
cells. By taking all this information in to consideration, the ways in which mutations in 
ABCA12 may be involved in the pathogenesis of Ichthyosis may be approached.  
4.1.4b Predicted Effect of Variant on Protein 
ABCA12 is known to be associated with Ichthyosis, and many different mutations within this 
gene have been documented to be the causative factor in numerous cases of Ichthyosis (figure 
10). By analysing where on the gene the mutation occurs, the resulting effect on the ABCA12 
protein may be predicted (figure 11), and in this way, the mechanism and genetic basis of the 
disease may begin to be elucidated.  
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Figure 10. ABCA12 Gene showing the Locations of Several Mutations already Identified, and 
location of Novel Missense Change (Modified from AC Thomas et al (2006)  The exons in the 
gene are shown in red. Missense changes can be found above the gene, while deletions can be found 
underneath the gene. The novel missense change identified in the two families is marked in red at 
exon 32.   
 
 
Figure 11. Schematic representation of the ABCA12 protein, and predicted location of 
Mutation; adapted from Akiyama et al (2006).  
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In order to assess the predicted effect the mutation will have on the function of the protein, 
the program called Polymorphism Phenotyping V.2 was used (PolyPhen, Harvard University 
(16). It takes into account how conserved the gene is, and the amino acid change in order to 
predict the likely effect on the function of the protein.ABCA12 is known to be highly 
conserved among all mammals, zebra fish and chicken, suggesting that it is assential (Figure 
12). It is therefore predicted that a mutation in exon 32, at 1559 Gly>Val will be ‘probably 
damaging’ (figure 13).  
 
H.sapiens       1535   HHLDEAEVLSDRIAFLEQGGLRCCGSPFYLKEAFGDGYHLTLTKKKSPNL   1584 
P.troglodytes   1535   HHLDEAEVLSDRIAFLEQGGLRCCGSPFYLKEAFGDGYHLTLTKKKSPNL   1584 
C.lupus         1534   HHLDEAEVLSDRIAFLEQGGLRCCGSPFYLKEAFGDGYHLTLTKKKSPNL   1583 
B.taurus        1473   HHLDEAEVLSDRIAFLEQGGLRCCGSPFYLKEAFGDGYHLTLTKKKSPNL   1522 
M.musculus      1532   HHLDEAEVLSDRIAFLEQGGLRCCGSPFYLKEAFGDGYHLTLTKKKSPNL   1581 
G.gallus        2763   HHLDEAEVLSDRIAFLEHGGLKCCGSPFYLKETFGDGYHLTLTKKKSVFL   2812 
D.rerio         2586   HHLDEAEVLSDRIAFLERGGLKCCGSPFYLKDKLAKGYNLTLTKKVETA-   2634 
 
Figure 12. Multiple sequence alignment of ABCA12. This sequence alignment of ABCA12 between 
species shows that the amino acid present at 1559 is highly conserved among all mammals, zebrafish 
and chicken.  
 
 
Figure 13. Predicted Effect of 1559 Gly>Val mutation on ABCA12 protein by PolyPhen V.2 Due 
to the fact that this gene is conserved among all species, and that the amino acid change is relatively 
significant, the predicted outcome is that this mutation will most likely have a damaging outcome on 
the ABCA12 protein.  
 
 
By analysing the results outlined in this study, it is clear that the mutation identified through 
whole exome sequencing for families 1 and 2 with Ichthyosis, is indeed highly likely to be 
the causative mutation for the disease. There is some evidence that implies that the mutation 
in ABCA12 in these two families has originated from a common ancestor, and been 
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transmitted to the affected individuals as a result of consanguineous matings. Though both 
families shared a common allele at D2S2944, no common allele was apparent at the other two 
microsatellite loci that mapped to the other side of ABCA12. Indeed in Family 1 there is 
evidence of a recombination between ABCA12and D2S164 (different alleles in ICH103 and 
ICH110 at D2S164). Thus it cannot be excluded that the two families, although previously 
thought to be unrelated and were observed to share a common conserved haplotype at 
D2S2944, might be distantly related in some way.  
 
4.1.5 Future Work 
ABCA12 has been identified to be the causative mutation in two families from Pakistan. It is 
thought that these families could be distantly related after careful analysis of linkage data 
collected from the individuals. The exact function of ABCA12 and the ways in which it 
contributes to Ichthyosis are still elusive, and therefore it may be beneficial to carry out 
functional assays on the gene. Furthermore, as this is a novel mutation identified in ABCA12 
it would be interesting to screen more suffers of Ichthyosis, particularly from consanguineous 
backgrounds in order to determine if this mutation exists in other families.  
 
4.2 Cerebral palsy 
Cerebral palsy (CP) is a heterogeneous group of neurological disorders, characterised by non-
progressive abnormalities in posture and motor function as a result of a defect in the 
development of the nervous system (21). It is estimated that 1 in approximately 250 to 1000 
neonates develops CP, therefore making it one of the most frequently occurring congenital 
disabilities (21).  Non-progressive forms of symmetrical, spastic CP have been identified, 
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which show a Mendelian autosomal recessive pattern of inheritance (21). CP can occur in an 
autosomal dominant, X-linked or autosomal recessive form. There are several different 
subtypes of CP, which are grouped based on their phenotypes (21). The groups are made up 
of Spastic CP, Dyskinetic CP which includes the choreoathetotic and dystonic subtypes, and 
Ataxic CP which includes congenital ataxia and ataxia diplegia subtypes (21,22). Of the three 
major groups, Spastic CP is the most prevalent, affecting approximately 70% of CP patients 
(21).  
Individuals with Spastic CP often display muscular hypertonicity, and stiffness of the limbs 
and extremities (21). 
A previous study described the case of two consanguineous families from the Mirpur region 
of Pakistan with non-progressive, autosomal recessive, symmetrical Spastic Cerebral palsy. 
The study described the mapping of a recessive spastic CP locus to a 5cM chromosomal 
region located at 2q24-31.1. The narrow region suggested that a mutation in GAD1 could 
potentially underlie the CP within these families, however it was later discovered that this 
was not the causative variant (21). This study therefore aimed to usewhole exome sequencing 
data to attempt to identify the causative variant responsible for their disease. Successful 
identification of the causal variant may provide insight into the possible mechanisms of 
pathogenesis, in addition to furthering knowledge and understanding of this disorder.  
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4.2.1 Methods 
DNA was provided by two related families from the Mirpur region of Pakistan. The 
pedigrees of the families can be found in figure 14.  
4.3.1a Patient Information and Pedigrees 
 
Figure 14. Pedigrees of the two families from Pakistan with CP(A) Family 1 from Pakistan with 5 
affected individuals. (B) Family 2, related to family 1 with 2 affected individuals.  
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4.2.1c Mutation Analysis of Candidate Genes 
Primers were designed as outlined in section 4.1.2 d for C8A and HPDL ensuring that the 
primers were designed to flank either side of the coding exon harbouring the mutation. These 
primers were used to amplify regions of interest of C8A and HPDL from DNA of the family 
(see methods section 3.1.3) Data was then analysed to determine which variant, if any, 
segregated within the family.  
 
4.2.2 Cerebral palsy Results 
4.2.2a Analysis of Exome Sequencing Data 
Whole exome sequencing data was provided for an individual from family 1. Through 
process of elimination, variants which were present in the dbSNP, or 1000 genomes project 
were excluded. The novel and non-synonymous changes were identified, and through this, 
the number of candidate variants was reduced from the original 29,431 to 59 variants. 
Information collected from previous studies on this family was provided by Dr. Neil Morgan; 
the studies suggested that the causal variant was within the region of chromosome 1 and in 
the range of 20,000 to 50,000.  
 
4.2.2a Analysis of Sequence Data 
The electropherograms received for the C8A data were analysed, however upon close 
inspection, it was found that there was a homozygous change for the mutation present in an 
unaffected individual. This implied that the mutation did not have a causative role in the 
development of the disorder. This gene was therefore ruled out as a candidate variant.  
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The electropherograms were then analysed for HPDL, and it was found that this variant 
segregated within both families (Figure 16). 
 
Figure 15.Electropherogram Data for HPDL (A) Electropherogram data for parent of Proband; the 
data clearly shows the parent to be a heterozygous carrier for the mutation (Leu176Pro A>G). (B) 
Affected individual from family 1, shows a homozygous genotype for the mutation. (C) Control DNA 
sample screened for the mutation, shows wild type genotype. The electropherogram data confirms that 
HPDL segregates in the two families, and that it is not present in the general population. 
 
4.2.3 Cerebral palsy Discussion 
4.2.3a HPDL and its associated Proteins 
TheHPDL variant segregated in both families, suggesting that it may be the causative 
mutation. HPDL, also known as 4-hydroxyphenylpyruvate dioxygenase-like, is made up of 1 
exon, however the understanding of its functions remain elusive. It is part of the HPD gene 
family which are known to be involved in the formation of an enzyme known as 4-
hydroxyphenylpyruvate dioxygenase. This enzyme is found in abundance in the liver and 
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kidneys, and it is thought to be involved in the breakdown of tyrosine (23). The precise 
function of HPDL however remains unknown, and therefore for future work, it would be 
important to carry out protein assays in order to fully elucidate the function of HPDL in order 
to determine whether HPDL is in-fact the causative mutation, and if so, to understand the role 
it may play in the occurrence of CP.  
 
4.2.3b Predicted Effect on Protein 
The effect that a mutation at Leu176Pro in HPDL may have on the resulting protein can be 
predicted using the program PolyPhen, as was done with ABCA12. The amino acid at 176 in 
HPDL is moderately conserved among species (figure 16), and this will be taken into account 
when predicting the consequences of a mutation at this location on the protein encoded.   
H.sapiens            139   RGPFLPGFRPVSSA-PGPGW----VSRVDHLTLACTPGSSPTLLRWFHDC   183 
P.troglodytes        139   RGPFLPGFRPVSSA-PGPGW----VSRVDHLTLACTPGSSPTLLRWFHDC   183 
C.lupus              139   RGPFLPGFQSVPSA-AGPGW----VSHVDHLTLACTPGSSPTLMRWFRHC   183 
B.taurus             139   GGPFLPGFSPVPST-PGPGW----FSHVDHLTLACNPSSSPKLLHWFHDC   183 
M.musculus           139   RGSFLPGFRPLPCT-PGPGW----VSHVDHLTLACTSGSSPMLMRWFHDC   183 
R.norvecicus        139   RGSFLPGFRPLPCT-PGPGW----VSHVDHLTLACTSGSSPTLMRWFHNC   183 
G.gallus             144   RGPFLPGFQPIRGAPPGDGAE---VSHFDHITYVCPRGGTQAALEWYRRC   190 
D.rerio              151   QGPFLPGFREVSSGCQGADRSRCPITHFDHITYACPRSSTVHITNWYRRN   200 
 
Figure 16. Multiple Sequence Alignment for HPDL This multiple alignment shows that HPDL is 
moderately conserved among species. It does not appear to be conserved in B.taurus, or D.rerio.  
 
The predicted effects of the variant on the resulting proteinfrom PolyPhen suggested that a 
Leu176Pro variation in HPDLwould be‘possibly damaging’. This suggests a possibility that 
the variant would be damaging, but it cannot be used as firm evidence. 
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4.2.3c Conclusions about HPDL and CP 
The variant in HPDL was found to segregate within the two families from Pakistan with CP. 
It is difficult to say with confidence however that this is without doubt the causative variant. 
Although this gene has not been documented before, and it was not present in the controls 
screened, or in the 1000 genomes database, this is still not sufficient evidence. For example, 
previous studies on this family suggested that the causative variant lied within a gene known 
as GAD1; however after investing much time and effort into this gene, it was found that 
GAD1, despite being a novel variant, and not present in the 1000 genomes database, was not 
responsible for the disease (21). This highlights some of the difficulties encountered with not 
only identifying a potential candidate variant, but to prove with 100% confidence that this 
variant is in fact the causative factor. 
4.2.4 Future Work  
 In order to fully determine with confidence whether this variant is the causative factor for the 
CP in these two families, further studies investigating the gene should be carried out. For 
example, the function of the protein encoded by HPDL should be investigated in order to 
determine if it has any links to the symptoms of the disease, or the pathogenesis of the 
disease. Furthermore, assays should be carried out in order to determine if the variant has any 
effect on the stability of the protein in vivo; information gathered from procedures such as 
these may give further insight into the ways in which this variant affects the individual, and 
the consequences associated with it. In addition, more individuals with similar phenotypes 
should be examined in order to determine if any of them share the same variant. Successful 
identification of the gene, and greater knowledge about the protein encoded may give 
opportunities to improve diagnosis of patients, or to develop genetic counselling in order to 
give patients an idea of the risks associated with having an affected child.  
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5.0 Discussion  
 
Recent developments in next generation sequencing technologies have revolutionised the way 
in which both rare and common diseases are currently investigated. The advances in abilities 
to cost-effectively, sequence numerous samples with high-throughput, in parallel, have 
facilitated researchers to identify disease-causing variants, and map their patterns of 
inheritance (10).   
Whole exome sequencing has enabled researchers to focus on critical parts of the genome, 
thereby permitting deeper sequencing of targeted regions in a greater number of samples. 
This reduces redundancy of information which may arise as a result of whole genome 
sequencing, as protein-coding genes, although only constituting approximately 1% of the 
genome, are known to contain close to 85% of causal variants with large consequences on 
disease-related phenotypes (10).  For this reason, the protein-coding region is usually the first 
location to be investigated when searching for causal variants associated with disease; 
therefore whole exome sequencing is a much more appropriate technique to employ than 
whole genome sequencing.   
 
5.1Whole Exome Sequencing to Identify Disease Genes 
Advances in next generation sequencing have revolutionised the ways in which monogenic 
disorders are approached. For example, single nucleotide polymorphism arrays are able to 
rapidly ascertain areas of homozygosity within the genome, and this information can be used 
to facilitate and reduce time required for linkage analysis which will highlight regions of 
interest (10). Use of linkage analysis data in consanguineous families can help to identify 
variants with a common ancestor, which are likely to be the causative mutation for a 
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particular disease. For example, the mutation found in ABCA12 which was unexpectedly 
identical between the two Pakistani families with Ichthyosis, gave strong evidence to suggest 
that the two families were distantly related in some way. 
 
5.2 Limitations of Exome Sequencing 
These approaches while possessing many advantageous qualities with regard to throughput 
are not without their limitations. These processes can often be rather expensive, and take 
time, and the success rate in identifying the causal variant is not always high. The main 
problem associated with these methods, is that a large sample size is required to provide 
reliable data; and due to the rarity of these particular diseases, this is often very challenging. 
For this reason, consanguineous families often provide a solid foundation for investigating 
recessive disease, due to the larger sample sizes with common, shared variants. By combining 
exome sequencing technologies and linkage data with consanguineous families, the task of 
distinguishing the links between causative variants and disease may be more achievable.  
The majority of Mendelian disorders are known to occur as a result of exonic or splice-site 
variants which result in an alteration in the amino acid sequence of a particular gene (10). In 
such cases, if sample sizes are of sufficient size, the identification of the causal variant is 
usually achievable; however limitations of exome sequencing become apparent when the 
causative mutation is located within an intron or promoter region of a gene. In these cases, 
the variant would not appear in the exome sequencing data, and would be overlooked as a 
possibility.  
Another frustration with exome sequencing can occur when the causal variant is identified 
successfully, however it has already been documented in literature surrounding the particular 
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disease. The international collaboration of the 1000 genomes project is advancing, and the 
creation of large, public databases of known variants should improve this problem, and save 
valuable time, effort and money.  
Finally, as in the case of HPDL identified for the families with Cerebral palsy in this study, 
on occasion, a variant which is believed to play a causative role in the disease may be 
discovered; however due to the fact that it has not been documented before, the challenges 
involved in proving that this is the correct gene are extensive. In order to provide strong 
evidence, more samples with similar phenotypes are required to determine if any share the 
mutation. In addition, in order to give light to the mechanisms of pathogenicity of the 
mutation, functional studies of the protein must be carried out. This can prove to be difficult, 
particularly when the knowledge surrounding the gene is elusive. Computer predictions, such 
as PolyPhen,may be used to predict the effect the variant may have on the protein encoded, 
however these results are not as reliable as an in vivo experiment may provide.  
 
5.3 Establishing the Genotype-Phenotype Relationship 
One further difficulty in the challenge to identify and understand the role of a causal variant 
in disease is to establish the relationship between the genotype and the resulting phenotype. 
Locus heterogeneity for example, is a concept which confuses matters; as variants in 
unrelated gene loci may contribute to cause a single disease. Furthermore, in some cases, a 
mutation in one gene may contribute to multiple phenotypes, while certain phenotypes can 
also be a result of a combination of multiple genes. For this reason, when a causal variant is 
identified, it can often be an extremely challenging task to gather sufficient evidence to 
conclude with confidence that the variant is the leading cause of the disease; particularly 
when the variant is novel, as in the case of HPDL.  
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5.4 Future Work and Prospects 
The fact that the processes involved in identifying and confirming a variant as the cause of a 
disease requires so much research gives a lot of prospects for future work. In the case of 
ABCA12, protein functional assays can be carried out in order to determine the effects on the 
protein caused by the mutation. In Vivo studies can be carried out, to establish whether this 
mutation may cause Ichthyosis in animal models in order to provide further evidence that it is 
a causative factor. Furthermore, protein functional assays may provide insight into the 
pathogenicity of the mutation and elucidate the role played by the variant in the occurrence of 
Ichthyosis in the two families discussed. By gathering additional samples with similar 
phenotypes, it can also be investigated as to whether further individuals hold this mutation.  
With regard to HPDL, a lot of work remains in order to fully determine whether this mutation 
is the causative factor. Due to the fact that this is a novel mutation, and has not been 
described in CP before, combined with the fact that there is not much information 
surrounding the gene, functional studies on the protein encoded will be more difficult. 
Research must first be carried out in order to establish gene function prior to investigating the 
effects the mutation may have on protein function. In addition, more samples may be required 
with similar phenotypes in order to determine if further individuals possess the same 
mutation. Finding more cases in which HPDL is suspected to cause CP will strengthen the 
evidence that HPDL is the causative factor in these cases.  
In conclusion, it is clear that a lot of work and effort is involved in order to identify causal 
variants through whole exome sequencing; however if successful, the prospects and wealth of 
knowledge that stand to be gained are large. There have been many successes gained from 
investigating disease through exome sequencing. Successful identification of a causal variant 
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for such diseases may provide the opportunities to develop new therapies, or improve 
diagnostic methods. In addition, useful results may facilitate screening of families, which 
may give informative information regarding the likelihood of having affected offspring. With 
continued research into this field, more genes will be identified and examined, and this may 
contribute greatly to the field of genomics and the ways in which we treat genetic diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
References 
1. Bittles AH, (2002) Endogamy, consanguinity and community genetics. Journal of 
Genetics. Vol. 81, No.3, Dec. 2002.  
2. Bittles AH, (2001) Consanguinity and its relevance to clinical genetics. Clinical 
Genetics 2001: 60: 89-98. 
3. Bittles AH, (2010) Consanguinity, human evolution, and complex diseases. 
PNAS.doi:10.1073/pnas.0906079106 
4. Alfonso-Sanchez MA, Pena JA. (2005). Effects of Consanguinity on Pre-
reproductive Mortality: Does Deomgraphic Transition Matter?.American Journal of 
Human Biology. 17:773-786. 
5. Bittles AH, (2007) Consanguineous Marriages and Childhood Health. 
Developmental Medicine and Child Neurology. 45:  571–576 
6. Hamamy H, Antonarakis SE, Luca L, Sforza C, Temtamy S, Romeo G, Ten Kate LP, 
Bennett RL, Shaw A, Megarbane A, Duikn CV, Bathija H, Fokstuen S, Engel E, 
Zlotogora J, Dermitzakis E, Bottani A, Dahoun S, Morris MA, Arsenault S, Aglan M, 
Ajaz M, Alkalamchi A, Alnageb D, Alwasiyah MK, Anwer N, Awwad R, Bonnefin 
M, Corry P, Gwanmesia L, Karbani GA, Mostafavi M, Pippucci T, Boscardin ER, 
Reversade B, Sharif SM, Teeuw ME, Bittles AH. (2011) Consanguineous marriages, 
pearls and perils: Geneva International Consanguinity Workshop Report. DOI: 
10.1097 
7. Carr IM, Flintoff KJ, Taylor GR, Markham AF, Bonthron DT. (2006) Interactive 
Visual Analysis of SNP Data for Rapid Autozygosity Mapping in Consanguineous 
Families. Human Mutation 27 (10) 1041-1046. 
8. Woods GC, Cox J, Springell K, Hampshire DJ, Mohamed MD, McKibbin M, Stern 
R, Raymond FL, Sandford R, Sharif SM, Karbani G, Ahmed M, Bond J, Clayton D, 
Inglehearn CF. (2006) Quantification of Homozygosity in Consanguineous 
Individuals with Autosomal Recessive Disease. American Journal of Human 
Genetics. Vol.78:889-896.  
9. Zhang J, Chiodini R, Badr A, Zhang G. (2011) The impact of next-generation 
sequencing on genomics. J Genet Genomics. 2011. March 20; 38(3): 95-109. 
10. Majewski J, Schwartzentruber J, Lalonde E, Montpetit A, Jabado N. What can 
Exome Sequencing Do for You? J Med Genet (2011). doi:10.1136/jmedgenet-2011-
100223 
11. The 1000 Genomes Project Conortium (2010) A Map of Human Genome Variation 
From Population-Scale Sequencing. Nature doiL10.1038.nature 09534. 
41 
 
12. L. Rodríguez-Pazos, M. Ginarte, L. Fachal, J. Toribio, A. Carracedo, A. Vega. (2011) 
Analysis of TGM1, ALOX12B, ALOXE3, NIPAL4 and CYP4F22 in Autosomal 
Recessive Congenital Ichthyosis from Galicia (NW Spain): evidence of founder 
effects.British Journal of Dermatology. DOI: 10.1111/j.1365-2133.2011.10454. 
13. LAkiyama, M. (2010) ABCA12 Mutations and Autosomal Recessive Congenital 
Ichthyosis: A Review of Genotype/Phenotype Correlations and of Pathogenetic 
Concepts. Human Genome Variation Society. D01 10.1002/humu.21326. 
14. Akiyama, M. (2006) Pathomechanisms of Harlequin Ichthyosis and ABCA 
Transporters in Human Diseases.Archives of Dermatology. 142:914-918. 
15. Akiyama  M, Sakai  K, Sugiyama-Nakagiri Y, Yamanaka Y, McMillan JR, 
Sawamura D, Niizeki H, Miyagawa S, Shimizu H. (2006)  Compound Heterozygous 
Mutations Including a De Novo Missense Mutation in ABCA12 Led to a Case of 
Harlequin Ichthyosis with Moderate Clinical Severity.  Journal of Investigative 
Dermatology. 126.1518-1523. 
16. Dzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, 
Kondrashov AS, Sunyaev SR. Nat Methods 7(4):248-249 (2010).  
17. Akiyama M, Nakagiri-YS, Sakai K, McMillan JR, Goto M, Arita K, Abe YT, Tabata 
N, Matsuoka K, Sasaki R, Sawamura D, Shimizu H. Mutations in Lipid Transporter 
ABCA12 in harlequin Ichthyosis and functional recovery by corrective gene transfer. 
Journal of Clinical Investigation (2005); 115(7): 1777-1784. 
18. Kohan ZG, Antonelli J, Cohen HA, Adar H, Chemke J. Further delineation of the 
acrocallosal syndrome. European Journal of Pediatrics. (1991). 150:797-799.  
19. Rehman F, Forshew T, Kurian MA, Cattell G, Farndon P, Brueton L, Maher E. A 
Novel Locus in a Family with an Acrocallosal-like Phenotype. Medical and 
Molecular Genetics, University of Birmingham 
 
20. A Putoux1, S Thomas, K L M Coene, E E Davis, Y Alanay, G Ogur, E Uz, DBuzas, 
CGomes, SPatrier, C L Bennett, N Elkhartoufi, M H Saint Frison, L Rigonnot, N 
Joyé, SPruvost, G E Utine, KBoduroglu, PNitschke, LFertitta, ClThauvin-Robinet, A 
Munnich, V Cormier-Daire, RHennekam, E Colin, N AAkarsu, C Bole-Feysot, N 
Cagnard, A Schmitt, NGoudin, SLyonnet, F Encha-Razavi1, J PSiffroi, M Winey, 
NKatsanis, MGonzales, MVekemans, P L Beales& TAttié-Bitach. KIF7 mutations 
cause fetalhydrolethalus and acrocallosalsyndromes.Nature Genetics (2010) 
doi:10.1038/ng.826. 
21. Lynex CN, Carr IM, Leek JP, Achuthan R, Mitchell S, Maher ER, Woods CG, 
Bonthon DT, Markham AF. Homozygosity for a missense mutation in the 67lDa 
isoform of glutamate decarboxylase in a family with autosomal recessive spastic 
cerebral palsy: parallels with Stiff-Person Syndrome and other movement 
disorders.BMC Neurology. (2004) doi:10.1186/1471-2377-4-20. 
42 
 
22. Coutinho P, Barros J, Zemmouri R, Guimaraes J, Alves C, Chorao R, Lourenco E, 
Ribeiro P, Loureiro J, Santos JV, Abdelmadijd H, Paternotte C, Hazan J, Silva MC, 
Prud’homme JF, Grid D. Clinical Heterogeneity of Autosomal Recessive Spastic 
Paraplegias. Archives of Neurology. (1999); 56:943-949.  
23. Genetics Home Reference. HPD Genes (2008) accessed 08/08/11. 
http://ghr.nlm.nih.gov/gene/HPD 
24. Clark MJ, Chen Rui, Lam HYK, Karczewski KJ, Chen R, Euskirchen G, Butte AJ, 
Snyder M. Performance comparison of Exome DNA sequencing technologies. 2011 
Nature; doi: 10.1038/nbt.1975 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
